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Abstract 
 
Background 
Endometriosis is an oestrogen-dependent benign condition which is characterised by the 
presence of endometrial-like glands and stroma outside the uterus. Women with 
endometriosis usually present with pelvic pain and/or infertility. Endometriosis is a leading 
cause of infertility. Endometriosis is commonly thought to result from implantation of viable 
shed endometrial fragments in the peritoneal cavity after retrograde menstruation through the 
fallopian tubes; and genetic and endometrial factors, coelomic metaplasia and dissemination 
of menstrual debris through blood and lymphatic vessels may also contribute to its 
pathogenesis. In endometriosis, immune cells may be unable to effectively target the shed 
menstrual debris and allow their implantation.  
 
Regulatory T cells (Tregs) are a group of immuno-suppressive lymphocytes that control other 
immune cells. In early pregnancy, Tregs suppress maternal immune responses to fetal 
antigens and prevent fetal rejection. Previous studies have demonstrated that Tregs are 
disturbed in women with endometriosis. Numbers of Tregs may be inadequate in unexplained 
infertility and sub-clinical pregnancy loss, yet their precise roles in endometriosis and 
associated infertility are unclear.  
 
Aims  
This project aimed to investigate the proportions and numbers of blood and endometrial 
Tregs in women with endometriosis and associated infertility. 
  
 
iv 
 
 
 
Methods 
Fertile and infertile women with and without endometriosis were recruited. Flow cytometry 
(n = 50) and immunohistochemistry (n = 88) were performed to analyse circulating and 
endometrial immune cell proportions and numbers, particularly Tregs, throughout the 
menstrual cycle.  
 
Results 
The overall results showed that numbers of Tregs and other lymphocytes differed in women 
with endometriosis, infertility and endometriosis-associated infertility in the menstrual cycle 
compared to controls. Endometrial Treg proportions were significantly increased during the 
proliferative phase in fertile compared to infertile women. Proportions of blood and 
endometrial live lymphocyte populations were increased during the proliferative phase in 
endometriosis, infertility and endometriosis-associated infertility.  
 
Conclusions 
This project provides new evidence for alterations in blood and endometrial Tregs and other 
lymphocyte populations in women with endometriosis, infertility and endometriosis-
associated infertility. The immune system is tightly regulated during the normal menstrual 
cycle and variations in these cyclical patterns at systemic and endometrial levels may 
contribute to reproductive pathologies such as endometriosis and infertility. There is an 
indication of increased survival of lymphocytes in blood and the endometrium in 
endometriosis and infertility before the window of implantation. Increased survival of 
lymphocytes around the peri-implantation period, possibly secondary to altered Treg count in 
infertile women, may contribute to an inflammatory endometrial environment and to 
endometriosis and infertility.  
v 
 
 
 
TABLE OF CONTENTS 
DECLARATION................................................................................................................ I 
ACKNOWLEDGEMENTS ............................................................................................. II 
ABSTRACT ..................................................................................................................... III 
TABLE OF CONTENTS ................................................................................................. V 
LIST OF FIGURES .......................................................................................................... X 
LIST OF TABLES ......................................................................................................... XII 
LIST OF ABBREVIATIONS ..................................................................................... XIV 
CHAPTER 1 ENDOMETRIOSIS .................................................................................... 1 
1.1 Introduction .................................................................................................................. 1 
1.2 Uterus and menstrual cycle ......................................................................................... 1 
1.3 Endometriotic lesions................................................................................................... 4 
1.3.1 Peritoneal endometriosis....................................................................................... 5 
1.3.2 Ovarian endometriosis .......................................................................................... 5 
1.3.3 Deep infiltrating..................................................................................................... 6 
1.4 Pathophysiology ........................................................................................................... 7 
1.4.1 Genetic factors ....................................................................................................... 7 
1.4.2 Theories of pathogenesis ....................................................................................... 7 
1.4.2.1 Coelomic metaplasia ....................................................................................... 7 
1.4.2.2 Implantation .................................................................................................... 8 
1.4.2.3 An endometrial disease .................................................................................. 8 
    1.4.2.4 An immune disease. ...................................................................................... 12 
1.5 Immunological changes ............................................................................................. 12 
1.5.1 Immune cells ........................................................................................................ 13 
1.5.2 Immune cell dysregulation in endometriosis .................................................... 14 
1.5.3 Cytokines and growth factors ............................................................................ 17 
1.6 Clinical aspects ........................................................................................................... 20 
1.6.1 Symptoms ............................................................................................................. 20 
1.6.1.1 Pelvic pain ..................................................................................................... 20 
1.6.1.2 Infertility........................................................................................................ 21 
vi 
 
 
 
1.6.2 Diagnosis .............................................................................................................. 21 
1.6.3 Treatment ............................................................................................................. 22 
1.6.3.1 Medical .......................................................................................................... 22 
1.6.3.2 Surgical .......................................................................................................... 22 
CHAPTER 2 ENDOMETRIOSIS-ASSOCIATED INFERTILITY AND 
REGULATORY T CELLS ............................................................................................. 24 
2.1 Introduction ................................................................................................................ 24 
2.1.1 Normal conception and implantation ................................................................ 24 
2.2 Infertility ..................................................................................................................... 25 
2.2.1 Immune aspects of female infertility ................................................................. 25 
2.3 Endometriosis-associated infertility ......................................................................... 27 
2.3.1 Mechanisms.......................................................................................................... 27 
2.3.1.1 Folliculogenesis and ovulation ..................................................................... 27 
2.3.1.2 Oocyte quality and function......................................................................... 28 
2.3.1.3 Sperm function .............................................................................................. 29 
2.3.1.4 Fertilisation and implantation ..................................................................... 29 
2.3.1.5 Peritoneal environment ................................................................................ 30 
2.4 Artificial reproductive techniques in endometriosis-associated infertility ........... 31 
2.5 T cell lineage ............................................................................................................... 32 
2.5.1 T cell development and antigen recognition ..................................................... 33 
2.5.2 Sub-populations of T cells................................................................................... 35 
2.6 Regulatory T cells ...................................................................................................... 36 
2.6.1 Lineage of regulatory T cells .............................................................................. 37 
2.6.2 Markers ................................................................................................................ 39 
2.6.3 Roles of dendritic and interleukins in development and function .................. 41 
2.6.4 Mechanisms of immune suppression.. ............................................................... 42 
2.6.5 Functions .............................................................................................................. 44 
2.6.6 Roles in diseases ................................................................................................... 45 
2.6.7 Effect of ageing on Treg numbers and function.. ............................................. 46 
2.7 Regulatory T cells in female reproduction .............................................................. 47 
2.7.1 In the ovary .......................................................................................................... 47 
2.7.2 The menstrual cycle ............................................................................................ 48 
2.7.3 Normal pregnancy ............................................................................................... 49 
2.7.4 Pregnancy-related complications. ...................................................................... 50 
2.7.5 Endometriosis ...................................................................................................... 53 
2.7.6 Possible roles of Tregs in endometriosis-associated infertility ........................ 55 
vii 
 
 
 
CHAPTER 3 HYPOTHESES, AIMS AND OBJECTIVES ........................................ 56 
3.1 Introduction ................................................................................................................ 56 
3.2 Hypotheses .................................................................................................................. 57 
3.2.1 Primary hypothesis ............................................................................................. 57 
3.2.2 Secondary hypotheses.. ....................................................................................... 57 
3.3 Aims ............................................................................................................................. 57 
3.4 Objectives.................................................................................................................... 58 
CHAPTER 4 METHODOLOGY ................................................................................... 59 
4.1 Ethics approval........................................................................................................... 59 
4.2 Sample size calculation .............................................................................................. 59 
4.3 Flow cytometry ........................................................................................................... 59 
4.3.1 Patient recruitment ............................................................................................. 59 
4.3.2 Collection of samples ........................................................................................... 60 
4.3.2.1 Blood .............................................................................................................. 60 
4.3.2.2 Endometrium ................................................................................................ 61 
4.3.3 Processing of blood and endometrial samples .................................................. 61 
4.3.3.1 Blood processing ........................................................................................... 61 
4.3.3.2 Dissociation of tissue ..................................................................................... 62 
4.3.4 Cell staining ......................................................................................................... 63 
4.3.4.1 Live/dead cell staining .................................................................................. 63 
4.3.4.2 Regulatory T cell staining ............................................................................ 64 
4.3.4.3 Fixation .......................................................................................................... 65 
4.3.5 Flow cytometer .................................................................................................... 66 
4.3.5.1 Fluidics ........................................................................................................... 67 
4.3.5.2 Lasers ............................................................................................................. 68 
4.3.5.3 Fluorescence .................................................................................................. 70 
4.3.5.4 Optics and detectors ..................................................................................... 71 
4.3.5.5 Noice, spectral overlap and compensation ................................................. 72 
4.3.5.6 Data acquisition and analysis ...................................................................... 74 
4.4 Immunohistochemistry .............................................................................................. 76 
4.4.1 Samples ................................................................................................................. 76 
4.4.2 Tissue processing ................................................................................................. 76 
4.4.2.1 Fixation .......................................................................................................... 76 
4.4.2.2 Tissue sectioning ........................................................................................... 77 
4.4.2.3 De-parafinisation and rehydration ............................................................. 77 
4.4.2.4 Antigen retrieval ........................................................................................... 77 
viii 
 
 
 
4.4.3 Autostainer ........................................................................................................... 78 
4.4.3.1 Wash buffer ................................................................................................... 78 
4.4.3.2 Blocking ......................................................................................................... 78 
4.4.3.3 Antibody ........................................................................................................ 78 
4.4.3.4 Amplifier........................................................................................................ 79 
4.4.3.5 Detection systems .......................................................................................... 79 
4.4.3.6 Visualisation .................................................................................................. 80 
4.4.3.7 Protocol .......................................................................................................... 80 
4.4.3.8 Positive and negative controls ..................................................................... 81 
4.4.4 Counterstaining and cover slipping ................................................................... 81 
4.4.5 Slide analysis ........................................................................................................ 81 
4.4.6 Statistical methods............................................................................................... 82 
CHAPTER 5 RESULTS .................................................................................................. 84 
5.1 Flow cytometry ........................................................................................................... 84 
5.1.1 Age distribution of patients ................................................................................ 84 
5.1.2 Blood immune cell changes in women with and without endometriosis ........ 84 
5.1.3 Endometrial immune cell changes in women with and without endometriosis
 .................................................................................................................................. …..87 
5.1.4 Blood immune cell changes in fertile and infertile women .............................. 89 
5.1.5 Endometrial immune cell changes in fertile and infertile women .................. 91 
5.1.6 Blood immune cell changes in endometriosis-associated 
infertility……………………………………………………………………..….……..94 
5.1.7 Endometrial immune cell changes in endometriosis-associated 
infertility………………………………………………………………………….....…98 
5.2 Immunohistochemistry ............................................................................................ 103 
5.2.1 Age distribution  ................................................................................................ 103 
5.2.2 Foxp3+ cells in women with and without endometriosis ............................... 103 
 
5.2.3 Foxp3+ cells in fertile and infertile women ..................................................... 105 
5.2.4 Foxp3+ cells in endometriosis-associated infertility .................................. .....106 
CHAPTER 6 DISCUSSION ......................................................................................... 108 
6.1 INTRODUCTION.................................................................................................... 108 
6.2 NORMAL MENSTRUAL CYCLE ........................................................................ 108 
6.2.1 Decreased survival of lymphocytes from the proliferative phase………… . 108 
6.2.2 Influx of immune cells and increased lymphocyte viability in the  
secretory phase ........................................................................................................... 110 
6.2.3 Variations in CD4+ cell count .......................................................................... 110 
6.2.4 Tregs in the secretory phase ............................................................................. 111 
ix 
 
 
 
 6.3 ENDOMETRIOSIS ................................................................................................ 112 
6.3.1 Increased survival of lymphocytes  .................................................................. 112 
6.3.2 CD4+ cell count ................................................................................................. 113 
6.3.3 Tregs in the secretory phase ............................................................................. 113 
6.4 INFERTILITY ......................................................................................................... 115 
6.4.1 Increased survival of lymphocytes from infertile women.............................. 115 
6.4.2 CD4+ cells in the proliferative phase ............................................................... 116 
6.4.3 Tregs in infertility.............................................................................................. 116 
6.5 ENDOMETRIOSIS-ASSOCIATED INFERTILITY .......................................... 118 
6.5.1 Increased survival of lymphocytes from endometriosis-associated 
infertility………………………………………………………………..………….....118 
6.5.2 CD4+ cells  ......................................................................................................... 119 
6.5.3 Tregs  .................................................................................................................. 120 
6.6 LIMITATIONS OF THE STUDY ......................................................................... 120 
6.7 CONCLUSIONS ...................................................................................................... 121 
6.8 FUTURE DIRECTIONS ......................................................................................... 123 
APPENDICES ................................................................................................................ 125 
REFERENCES ............................................................................................................... 126 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
 
 
LIST OF FIGURES 
Figure 1.1 Different phases of the menstrual cycle  .................................................... 3 
Figure 1.2 Common locations for endometriotic lesions ............................................ 4 
Figure 1.3 Laparoscopic appearances of (a) red lesion and (b) scarred white  
lesion of peritoneal endometriosis  ................................................................................ 5 
Figure 1.4 Laparoscopic appearance of a chocolate cyst ............................................ 6 
Figure 1.5 Deep infiltrating endometriosis  ................................................................. 6 
Figure 2.1 Regulatory T cells are selected in the thymus ......................................... 34 
Figure 2.2 Developmental pathways and markers of Treg sub-groups. ................. 38 
Figure 2.3 Treg have four mechanisms of action  ..................................................... 43 
Figure 2.4 Comparison of endometrial Treg numbers in women with and  
without endometriosis ….. ........................................................................................... 53 
Figure 4.1 Components of a blood sample in a BD Vacutainer Cell Preparation  
Tube after centrifugation  ........................................................................................... 62 
Figure 4.2 Fab (tip) and Fc (tail) fragments of Y-shaped antibody  ........................ 64 
Figure 4.3 Primary components of a flow cytometer ................................................ 67 
Figure 4.4 Hydro-dynamic focussing  ......................................................................... 68 
Figure 4.5 Laser light is diffracted in all directions after striking a cell. ................ 69 
Figure 4.6 Forward versus side scatter plot identifies leukocyte populations  ....... 70 
Figure 4.7 Light source excites the antibody-labelled cell electrons to a higher  
energy level.................................................................................................................... 71 
Figure 4.8 Spectral properties of two imaginary fluorochromes  ............................ 73 
Figure 4.9 Gating strategy for identification of Tregs  ............................................. 75 
Figure 4.10 Foxp3 were identified by dark brown staining of Treg nuclei ............ 82 
Figure 5.1 Comparison of median numbers of Tregs, CD4+ cells and live  
lymphocytes between women with and without endometriosis  .............................. 86 
Figure 5.2 Comparison of median numbers of endometrial Tregs, CD4+ cells  
and live lymphocytes between women with and without endometriosis ................. 89 
Figure 5.3 Comparison of median numbers of blood Tregs, CD4+ cells  
and live lymphocytes between fertile and infertile women  ...................................... 91 
Figure 5.4 Comparison of median endometrial numbers of Tregs, CD4+ 
 cells and live lymphocytes between fertile and infertile women  ............................ 94 
Figure 5.5 Overall median densities of blood Tregs, CD4+ cells and live  
lymphocytes in fertile and infertile women with and without endometriosis  ........ 97 
Figure 5.6 Median densities of blood Tregs, CD4+ cells and live  
lymphocytes in fertile and infertile women with endometriosis . ............................ 98 
Figure 5.7 Overall median densities of endometrial Tregs, CD4+ cells  
and live lymphocytes in fertile and infertile women with and without  
endometriosis  ............................................................................................................. 101 
Figure 5.8 Median densities of endometrial Tregs, CD4+ cells and live  
lymphocytes in fertile and infertile women with endometriosis  ........................... 102 
Figure 5.9 Comparison of median densities of Foxp 3+ cells between women 
 with and without endometriosis ….. ........................................................................ 104 
xi 
 
 
 
Figure 5.10 Comparison of median densities of Foxp3+ cells between fertile and 
infertile women  .......................................................................................................... 106 
Figure 5.11 Density of Foxp3+ cells in fertile and infertile women with and  
without endometriosis  ............................................................................................... 107 
  
xii 
 
 
 
LIST OF TABLES 
Table 1.1 Endometrial anomalies in eutopic endometrium from women with 
endometriosis compared to women without endometriosis  ................................... ….10 
Table 1.2 Immune cell population changes during the normal menstrual cycle 
……………………………………………………………………………………............15 
Table 1.3 Alterations in immune cell populations in women with endometriosis 
compared to women without the disease  ...................................................................... 16 
Table 1.4 Important cytokines and their possible roles in endometriosis .................. 18 
Table 2.1 Immune disturbances in female infertility .................................................... 26 
Table 2.2 Classification of T cells  .................................................................................. 36 
Table 2.3 Differences between regulatory T cell subsets  ............................................. 39 
Table 2.4 Treg markers in humans  ............................................................................... 40 
Table 2.5 Roles of important interleukins (ILs) in regulatory T cell (Treg)  
development  ..................................................................................................................... 42 
Table 4.1 Fluorochromes used in this experiment ….. ................................................. 65 
Table 4.2 Peak excitation and emission wavelengths of fluorescent dyes used 
in this experiment  ............................................................................................................ 71 
Table 5.1 Median densities and interquartile ranges of blood Tregs,  
CD4+ cells and live lymphocytes in the menstrual cycle in women with and  
without endometriosis  ..................................................................................................... 85 
Table 5.2 Median densities and inter-quartile ranges of endometrial Tregs, 
 CD4+ cell and live lymphocytes in the menstrual cycle in women with and  
without endometriosis  ..................................................................................................... 87 
Table 5.3 Median densities and interquartile ranges of blood Tregs,  
CD4+ cells and live lymphocytes in the menstrual cycle in fertile and infertile  
women  .............................................................................................................................. 90 
Table 5.4 Median densities and interquartile ranges of endometrial Tregs, 
 CD4+ cells and live lymphocytes in the menstrual cycle in fertile and infertile 
 women ….. ....................................................................................................................... 92 
Table 5.5 Median densities and interquartile ranges of blood Tregs,  
CD4+ cells and live lymphocytes in the menstrual cycle in fertile and infertile 
 women with and without endometriosis  ...................................................................... 97 
Table 5.6 Median densities and interquartile ranges of endometrial Tr egs,  
CD4+ cells and live lymphocytes in the menstrual cycle in fertile and infertile 
 women with and without endometriosis.  ..................................................................... 99 
Table 5.7 Median densities and interquartile ranges of Foxp3 in the  
menstrual cycle in women with and without endometriosis  ..................................... 103 
Table 5.8 Median densities and interquartile ranges of Foxp3+ cells in the  
menstrual cycle in fertile and infertile women  ........................................................... 105 
Table 5.9 Median densities and interquartile ranges of Foxp3+ cells in the 
menstrual cycle in fertile and infertile women with and without endometriosis 
…………………………………………………………………………………..….…..106 
  
xiv 
 
 
List of abbreviations  
Ang-2  Angiopoietin-2  
APCs   Antigen presenting cells 
ART  Assisted reproductive techniques  
Bax   Bcl-2 associated X protein  
Bcl 2  B cell lymphoma 2 gene  
17 β HSD-1  17 beta hydroxysteroid dehydrogenase-1  
C3   Complement component C3  
CA 125   Cancer antigen/Carbohydrate antigen 125  
CD   Cluster of differentiation 
CL   Corpus luteum 
CTLA-4   Cytotoxic T lymphocyte associated protein- 4  
CXCR-3   Chemokine receptor-3  
DCs   Dendritic cells  
DN   Double negative  
DNA   Deoxy-ribonucleic acid  
DP   Double positive  
EGF   Epidermal growth factor  
ER  Oestrogen receptor  
FF  Follicular fluid 
Foxp3   Forkhead box protein3  
FSH   Follicle stimulating hormone  
GAP-43   Growth associated protein-43 
GITR   Glucocorticoid induced tumour necrosis factor receptor  
GnRH   Gonadotropin releasing hormone  
HO-1   Heme-oxygenase-1  
ICSI   Intra-cytoplasmic sperm injection 
IDO   Indoleamine- 2,3-dioxygenase  
Ig    Immunoglobulin  
IL   Interleukin 
IFN   Interferon  
iTreg   Induced Treg  
IVF   In-vitro fertilisation  
LAG-3   Lymphocyte activation gene-3  
xv 
 
 
LH   Luteinizing hormone  
LIF   Leuko-cyte migration Inhibitory Factor  
MHC   Major histocompatibility complex  
MCP-1  Monocyte chemo-attractant protein 1  
MFR   Monthly fecundity rate  
MIF   Macrophage migration inhibitory factor  
MMPs  Matrix metalloproteinases  
MRI   Magnetic resonance imaging  
mRNA  Messenger ribo-nucleic acid  
NGF   Nerve growth factor  
NKs   Natural killer cells  
NKTs   Natural killer T cells  
Nrp-1   Neuropilin-1  
nTreg   Natural Treg  
OCPs   Oral contraceptive pills  
PAI-1   Plasminogen activator inhibitor-1  
PB   Peripheral blood  
Pdcd-1  Programmed cell death-1  
PGE2   Prostaglandin E2  
PF   Peritoneal fluid  
PGI 2   Prostaglandin I 2  
POF   Premature ovarian failure  
PR   Progesterone receptor   
RANTES  Regulated on activation, normal T cell expressed and secreted  
ROS   Reactive oxygen species  
RSA   Recurrent spontaneous abortion  
sICAM  Soluble intercellular adhesion molecule  
suPAR  Soluble urokinase-type plasminogen activator receptor 
sVEGFR  Soluble VEGF receptors 
TCR   T cell receptor 
TGF  Transforming growth factor  
Th   Helper T cells 
TIMPs  Tissue inhibitors of matrix metalloproteinases 
TNF-α  Tumor necrosis factor-alpha  
Treg   Regulatory T cell 
xvi 
 
 
TVS   Trans-vaginal ultrasound  
VEGF-A   Vascular endothelial growth factor-A  
WHO   World Health Organisation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
CHAPTER 1: ENDOMETRIOSIS 
 
1.1 INTRODUCTION 
Endometriosis is a benign oestrogen-dependent gynaecological condition. It is characterised 
by the presence of functional endometrial-like glands and stroma outside the uterus 
(Sampson, 1927). Endometriosis is a chronic, progressive and debilitating disease and it 
adversely affects the quality of life of women. It is manifested commonly as pelvic pain 
and/or infertility (Hwang et al., 2012, Nezhat et al., 2012).  
 
The reported overall incidence of endometriosis is 5–15 % in reproductive age women 
(Bulun, 2009). Since surgical visualisation is the gold standard for diagnosis, this may just be 
the ‘tip of the endometriosis iceberg’ and the true incidence of endometriosis be under-
reported in asymptomatic population. Between 1-7 % of women having tubal sterilisation are 
diagnosed with ‘incidental’ endometriosis with visualisation of pelvis (ASRM, 2012). 
  
1.2 UTERUS AND MENSTRUAL CYCLE 
The body of the uterus is histologically composed of an inner mucosal endometrium with 
glands and stroma, an outer fibro-muscular myometrium and the outermost layer of 
connective tissue covered by peritoneum (the perimetrium). Based on histology and function, 
the endometrium can be divided into three layers; the superficial stratum compactum and 
stratum spongiosum (together forming stratum functionalis) and the deeper stratum basalis. 
The stratum functionalis is sloughed off during menstruation and is the site of cyclic changes 
in the endometrium. The stratum basalis does not take part in menstruation and is the 
regenerative zone for zona functionalis (Lebrun, 1993, Salamonsen, 1998, Evans et al., 
2012). 
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Female reproduction depends on the cyclical development of the endometrium (menstrual 
cycle) and release of eggs (ovulation) from the ovary under influence of certain hormones. 
Disturbances in the menstrual cycle, ovulation or the balance of hormones can result in 
reproductive pathology (Mansfield and Emans, 1984). An overview of the female 
reproductive physiology is given below.  
 
The menstrual cycle and ovulation are dependent on an intricate balance of hormones 
released by the hypothalamus, pituitary and ovaries - the hypothalamic-pituitary-ovarian 
(HPO) axis. Gonadotropin releasing hormone (GnRH) is released from the hypothalamus. 
Pulsatile GnRH secretion stimulates release of follicle stimulating hormone and luteinising 
hormone from the pituitary, which are transported to the ovary through the blood 
(Salamonsen, 1998). FSH facilitates the development of ovarian follicles and selection of a 
dominant follicle for ovulation. LH promotes production of androgenic hormones, which are 
converted into oestrogens under the influence of FSH (Mansfield and Emans, 1984).   
 
The menstrual cycle is divided into three phases (menstrual, proliferative and secretory), 
which are based on hormone-dependent histological changes in the functional layer of 
endometrium (Evans et al., 2012) (Figure 1.1). The average cycle is 28 days but may vary 
from individual to individual. The normal range is 21 to 35 days (Lebrun, 1993). 
  
 
 
3 
 
 
 
 
Figure 1.1. Different phases of the menstrual cycle  (Catalano et al., 2011). 
Menstruation (days 1-3): In the absence of fertilisation, the corpus luteum (formed in the 
secretory phase) ceases to produce progesterone and removes negative feedback on the 
pituitary. Decreased levels of progesterone and LH result in constriction of the spiral 
arterioles and ischaemia of the endometrium. The arterioles rupture and shedding of the 
necrotic functional layer takes place (Salamonsen, 1998, Evans et al., 2012) (Figure 1.1). 
 
Proliferative Phase (days 4-14):  Under the influence of oestradiol secreted by ovarian 
follicles, the endometrium thickens, glandular structures in the stratum functionalis open out 
onto the surface and arteries and connective tissue renews. In the late-proliferative phase, 
oestradiol exerts a positive feedback on the pituitary and induces a pre-ovulatory surge of LH 
to facilitate release of egg from the dominant ovarian follicle (ovulation) (Figure 1.1) (Evans 
et al., 2012).  
 
Secretory Phase (days 15-28): After ovulation, the ovarian follicle becomes a corpus luteum 
(CL) which is a temporary progesterone-synthesising endocrine structure (Figure 1.1) 
(Mansfield and Emans, 1984). Progesterone modifies the endometrial lining to allow for 
embryo implantation (Greydanus and McAnarney, 1982, Salamonsen, 1998). The 
endometrial glands become cork-screw shaped and secrete a glycogen rich secretion. The 
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endometrial stromal changes include increased mitosis, oedema and infiltration of white 
blood cells (leukocytes) (Salamonsen, 1998, Evans et al., 2012). 
 
1.3 ENDOMETRIOTIC LESIONS 
Endometriosis commonly involves parts of the female pelvis like the ovaries, anterior and 
posterior cul-de-sac, fallopian tubes and utero-sacral ligaments as illustrated in Figure 1.2. 
The bowel can be affected, most often in the advanced stages of the disease (Nezhat et al., 
2011); bladder involvement does occur but is uncommon (Mettler et al., 2008); while other 
organs (like skin and lungs) are rarely affected (Wong et al., 1995, Chatzikokkinou et al., 
2009, Huang et al., 2013). In the pelvis, endometriosis may be present in three forms: 1) 
Peritoneal endometriosis, 2) Ovarian endometriosis and 3) Deep infiltrating endometriosis 
(DIE).  
 
 
Figure 1.2. Common locations for endometriotic lesions. 
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1.3.1 PERITONEAL ENDOMETRIOSIS 
Peritoneal lesions are further classified into red, black and white types according to their 
appearance during laparoscopy (Jansen RP, 1986, Nisolle et al., 1993). Red lesions are 
considered as the initial form of endometriosis (Figure 1.3a). They have an extensive blood 
supply, giving their characteristic appearance (Nisolle and Donnez, 1997). Cyclical growth 
and menstrual ‘shedding’ of the tissue induces an inflammatory reaction and a ‘scarification’ 
process (Nisolle et al., 1993). As a result, the lesion appears as ‘black’ due to intra-luminal 
debris (Nisolle and Donnez, 1997). In some cases, the inflammation causes fibrosis and de-
vascularisation of the implants, giving a ‘white’ or yellow-brown appearance (Figure 1.3 b).  
 
a.  b.  
Figure 1.3. Laparoscopic appearances of (a) red lesion and (b) new blood vessels around a scarred white 
lesion of peritoneal endometriosis (Fraser, 2008). 
1.3.2 OVARIAN ENDOMETRIOSIS 
In the ovaries, endometriosis typically presents as an endometrioma. Cyclical menstrual 
bleeding in the endometriotic cyst results in accumulation of characteristic thick-brown fluid 
and gives it the name ‘chocolate cyst’ (Redwine, 1987, Nisolle and Donnez, 1997) (Figure 
1.4).  
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Figure 1.4. Laparoscopic appearance of a chocolate cyst  (Fraser, 2008).  
 
1.3.3 DEEP INFILTRATING 
Endometriotic lesions penetrating the peritoneum by at least 5mm are considered to be deep 
(Kinkel et al., 1999, Mabrouk et al., 2011). Common sites of deep endometriosis include the 
infiltrative forms involving bladder, ureters, bowel and recto-vaginal tissue (Kinkel et al., 
1999). Deep lesions cause inflammation and fibrosis in the surrounding tissues, retraction of 
the rectal mucosa and nodule formation in the utero-sacral ligaments (Redwine, 1987, Nisolle 
and Donnez, 1997) (Figure 1.5).  
 
 
Figure 1.5. Deep infiltrating endometriosis showing focal infiltration and retraction of utero-sacral 
ligament (Chamié et al., 2011). 
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1.4 PATHOPHYSIOLOGY 
1.4.1 GENETIC FACTORS 
Endometriosis is a polygenic disorder with multiple allelic variations (Dun et al., 2010, 
Ballester et al., 2012, Layman, 2013). Women have a seven times greater risk of developing 
endometriosis if they have one first degree relative with the disease (Moen and Magnus, 
1993) and more severe forms are associated with a family history of the disease (Moen and 
Magnus, 1993, Nouri et al., 2010). Twin studies also support a genetic basis of this disease 
(Treloar et al., 1999). 
 
An association of endometriosis with genes such as HLA-B7, GALT, ABO, pseudo-choline-
esterase, transferrin, C3 and phospho-gluco-mutase has been described (Simpson et al., 1980, 
Cramer et al., 1996, Treloar et al., 1999). More recently, it is shown that mutations at 7p15.2, 
1p36, 2p25, 12q22, 2p14, 6p22.3 and 9p21.3 are associated with the increased risk of 
developing endometriosis (Painter et al., 2011, Nyholt et al., 2012).  
 
1.4.2 THEORIES OF PATHOGENESIS 
While the exact cause and pathogenesis of endometriosis remains unknown, there are a range 
of theories which have been proposed to explain its development. 
 
1.4.2.1 COELOMIC METAPLASIA  
The theory of coelomic metaplasia proposes that endometriosis develops from cells of the 
peritoneal cavity, such as the germinal epithelium of the ovary, which change by metaplasia 
into endometrial-like tissue (Iwanoff, 1898). This theory could explain the presence of 
endometriosis on the ovaries and peritoneum and in the absence of menstruation (Doty et al., 
1980, Vinatier et al., 2001, Mok-Lin et al., 2010). However, several observations argue 
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against this theory: 1) endometriosis does not affect males, 2) metaplasia is not manifested in 
every tissue derived from coelomic epithelium (for example, pericardium) and 3) the 
incidence of common metaplasia increases with age. However, the incidence of 
endometriosis does not (Vinatier et al., 2001). 
 
1.4.2.2 IMPLANTATION 
According to the theory of implantation, endometrial tissue shed at menstruation is refluxed 
through the fallopian tubes and can implant in the abdominal cavity as endometriotic lesions 
(Sampson, 1927). This theory is widely accepted as the observed location of lesions 
correspond to tubal reflux and shed endometrial cells are viable and capable of implantation 
(Tabibzadeh, 1992, Vinatier et al., 2001). In addition, women with increased exposure to 
menstruation, for example, shorter menstrual cycles of less than or equal to 27 days and 
longer than one week of flow, have more than double the risk of developing endometriosis 
(Cramer et al., 1986, Viganò et al., 2004, Larosa et al., 2010). However, this theory fails to 
explain the presence of disease at distant sites and why only some women develop 
endometriosis, although retrograde menstruation occurs in almost all women with patent 
fallopian tubes (Halme et al., 1984). 
 
1.4.2.3 AN ENDOMETRIAL DISEASE 
As discussed above, retrograde menstruation is a quasi-universal phenomenon but 
endometriosis occurs in only 5-15 % of women (Bulun, 2009). Evidence shows that in 
endometriosis, the eutopic endometrium is altered compared to women without the disease in 
a number of ways. This may facilitate establishment of endometriotic lesions from menstrual 
tissue following retrograde flow, which suggests that the primary defect in endometriosis 
may be in the uterine endometrium (Vinatier et al., 2000, Sharpe-Timms, 2001, Ulukus and 
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Arici, 2005, Al-Jefout et al., 2009). Endometrial anomalies in the eutopic endometrium of 
women with endometriosis are outlined in Table 1.1.  
 
Table 1.1. Endometrial anomalies in eutopic endometrium from women with endometriosis compared to 
women without endometriosis.  
Endometrial 
anomaly 
Description and 
pathogenic 
implications 
Specific molecules Expression References 
Apoptosis Percentage of 
endometrial cells 
undergoing apoptosis is 
significantly ↓ which 
allows more viable 
cells to reach the 
peritoneal cavity  
B cell lymphoma 2 gene 
and Bcl-2 associated X 
protein mRNA 
↓ (Gebel et al., 1998, 
Meresman et al., 2000, 
Braun et al., 2002, 
Johnson et al., 2005, 
Burlev et al., 2006, 
Braun et al., 2007) 
Immune 
components 
 
-Disturbed immune cell 
densities 
- ↑ inflammation 
-↓mitogenicity for 
lymphocytes 
-↑ resistance to 
cytotoxicity 
-Allows endometrial 
fragments to escape 
immune destruction  
See section 1.4.2.4 Variable (Isaacson et al., 1990, 
Oosterlynck et al., 1991, 
Nip et al., 1994, 
Klentzeris et al., 1995, 
Akoum et al., 1995, Ota 
et al., 1996, Tseng et al., 
1996, Helvacioglu et al., 
1997, Jolicoeur et al., 
1998, Piva et al., 2001, 
Bergqvist et al., 2001, 
Kyama et al., 2006, 
Kyama et al., 2008) 
Cell adhesion 
molecules 
(CAMs) 
Facilitate ectopic 
attachment of 
endometrial fragments 
Soluble intercellular 
adhesion molecule, 
integrins, cadherin and 
selectins 
↑ (some 
conflicting 
data) 
(Lessey et al., 1994, 
Somigliana et al., 1996, 
Ota et al., 1996, Viganò 
et al., 2004 , Kyama et 
al., 2008, Sundqvist et 
al., 2012) 
Proteases and 
their 
inhibitors 
↑ proteolytic activity 
and facilitation of 
peritoneal invasion 
Matrix 
metalloproteinases, 
cathepsin B, D and G, 
plasminogen activator 
inhibitor-1, soluble 
urokinase-type 
plasminogen activator 
receptor  
↑ (some 
conflicting 
data)  
(Bruner et al., 1997, 
Chung et al., 2001, 
Guan et al., 2002, 
Chung et al., 2002, 
Collette et al., 2004, 
Zhou et al., 2004, 
Collette et al., 2006, 
Kyama et al., 2006, 
Gaetje et al., 2007, Di 
Carlo et al., 2009, 
Laudanski et al., 2013) 
Tissue inhibitor of 
metalloproteinases  
↓ (Chung et al., 2001, 
Chung et al., 2002, Zhao 
et al., 2007) 
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Proliferation ↑ proliferation of shed 
endometrial fragments 
Ki67 and epidermal 
growth factor, telomerase 
and telomerase length 
and transforming growth 
factor- beta  
↑ 
 
(Wingfield et al., 1995, 
Jones et al., 1995, 
Osteen et al., 1996, 
Jürgensen et al., 1996, 
Scotti et al., 2000, 
Burlev et al., 2006, Kim 
et al., 2007, Park et al., 
2009, Aghajanova et al., 
2010) 
Angiogenesis Establishment of blood 
supply to implanted 
fragments 
Vascular endothelial 
growth factor-A, soluble 
Vascular endothelial 
growth factor receptors-1 
and 2, angiogenin, and 
angiopoietin-2 and blood 
vessel density 
↑ (Donnez et al., 1998, 
Kressin et al., 2001, 
Burlev et al., 2005, 
Burlev et al., 2006, 
Cosín et al., 2009, Di 
Carlo et al., 2009, 
Bourlev et al., 2010, 
Hey-Cunningham et al., 
2010) 
Neurogenesis In growth of nerve 
fibres and roles in 
endometriosis 
associated pain 
Nerve growth factor , 
nerve growth factor 
receptors, transforming 
growth factor- α, growth 
associated protein-43, 
prostaglandin I 2 and 
nerve fibre density 
↑ (Ylikorkala and 
Viinikka, 1983, Okragly 
et al., 1999, Bergqvist et 
al., 2001, Tokushige et 
al., 2006, Bokor et al., 
2009) 
Steroid 
production 
-Tissue production of 
oestrogen which 
promotes growth of 
ectopic lesions 
Aromatase P450, 17 beta 
hydroxysteroid 
dehydrogenase-1  
↑ (Wingfield et al., 1995, 
Zeitoun et al., 1998, 
Vinatier et al., 2000, 
Kitawaki et al., 2002, 
Hudelist et al., 2007, 
Bukulmez et al., 2008, 
Maia et al., 2012) 
Steroid 
receptor 
expression 
State of progesterone 
resistance inhibits 
matrix 
metalloproteinases  and 
contributes to 
oestrogen dominance 
-Progesterone receptors 
A and B and oestrogen 
receptor alpha  
-Oestrogen receptor beta 
↓ 
 
 
↑ 
(Fujishita et al., 1997, 
Attia et al., 2000, 
Matsuzaki et al., 2001, 
Igarashi et al., 2005, 
Bulun et al., 2006, 
Trukhacheva et al., 
2009)  
 
Eutopic endometrium in women with endometriosis differs from the normal endometrium 
during all menstrual cycle phases in a variety of ways (Sharpe-Timms, 2001, Akoum et al., 
2007, Al-Jefout et al., 2009). As detailed in Table 1.1, several characteristic features 
including reduced apoptosis, dysregulated immune response and increased adhesiveness, 
proteolysis, proliferation, angiogenesis, neurogenesis and local oestrogen production are 
evident in the endometrium from women with endometriosis. These eutopic endometrial 
anomalies in endometriosis are hypothesised to enable the establishment and persistence of 
12 
 
 
 
endometriotic lesions from the refluxed endometrium and indicate that an innate endometrial 
aberration is central to the pathogenesis of endometriosis.   
 
1.4.2.4 AN IMMUNE DISEASE 
As touched upon in section 1.4.2.3 above, it is suggested that immune dysfunction 
contributes to the implantation of endometrial fragments and progression of endometriosis. 
The endometrial, peritoneal and blood immune cell populations in women with endometriosis 
differ from those of women without the disease, leading to the theory of endometriosis as an 
immune disease (Vinatier et al., 1996, Ho et al., 1997, Ulukus and Arici, 2005). The theory 
hypothesises that central to endometriosis pathogenesis is failure of the immune system to 
clear shed and refluxed endometrial tissue and to protect the peritoneal cavity from its 
adhesion and invasion. Specific immunological changes in endometriosis are discussed in 
detail in section 1.5. Adding support to this theory, endometriosis also fulfils the criteria for 
auto-immune diseases such as abnormalities of B and T cell function, production of auto-
antibodies, tissue damage and multi-organ involvement (Weed et al., 1980, Mathur, 2000, 
Eisenberg et al., 2012). 
 
1.5 IMMUNOLOGICAL CHANGES 
Endometriosis is an enigmatic disease. The theories of pathogenesis discussed above (in 
section 1.4) can be linked by a defective immune system. In addition to the hypothesised 
permissive role of immune dysfunction in the implantation theory, in the metaplasia theory, 
growth and other factors resulting from immune activation may induce metaplasia of the 
inflamed mesothelium (Vinatier et al., 1996). Indeed, immunological changes are found to be 
associated with endometriosis and its consequences (Vinatier et al., 1996, Ulukus and Arici, 
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2005). It is, however, as yet unknown what triggers the immune system in endometriosis and 
whether these changes are primary or secondary to the disease (Berbic and Fraser, 2011).   
 
Broadly speaking, the human immune system is divided into innate and adaptive immunity. 
The innate system is the first line of defence against foreign substances. It is comprised of 
immune cells such as the phagocytic cells (which ingest dead bacteria or harmful foreign 
bodies), important cytokines released by the immune cells, antibodies (proteins which 
identify and neutralise foreign bodies) and the complement system (made up of protein 
digesting enzymes which “complement” the antibodies, phagocytic cells and released 
cytokines once activated). In contrast to innate immunity, adaptive immunity is specific to 
antigens and has a memory of pathogens to which an individual has been previously exposed. 
An antigen can be a toxin or pathogen, which stimulates antibody production. Adaptive 
immunity involves the antigen-presenting cells (APCs) such as dendritic cells (DCs), 
lymphocytes and their released cytokines (lymphokines) and antibodies (Colacurci et al., 
1991, Rier and Yeaman, 1997).  
1.5.1 IMMUNE CELLS   
Immune cells consist of the killer cells (such as the natural killer cells), the phagocytes (such 
as macrophages), APCs (such as dendritic cells [DCs]) and the lymphocytes (T and B). The 
Natural killer cells (NKs) are granular lymphocytes of the innate immune system (Manaster 
and Mandelboim, 2008) which have spontaneous cytotoxicity against tumour cells, virus 
infected cells and other cells (Gill, 2010). Macrophages engulf cellular debris and pathogens 
by phagocytosis (Oral et al., 1996). Dendritic cells recognise and capture antigens, 
process antigen material, present it on their cell surface to T cells and induce an immune 
response from T and B cells (Banchereau and Steinman, 1998, McKenna et al., 2005). B cells 
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function to make antibodies against antigens, perform suppressive functions by production of 
granzymes (cell death inducing proteases) and can act as antigen-presenting cells (Mauri and 
Bosma, 2012, Klinker and Lundy, 2012).
 
T cells are a subset of lymphocytes which defend the body against tumour cells and 
pathogenic organisms, initiate antigen-specific T cell responses to fetal antigens and produce 
cytokines that can have a role in maintenance or failure of pregnancy (Piccinni, 2005). They 
are further divided into cytotoxic (CD8+), which destroy specific targets and the helper 
(CD4+) T cells which transmit signals from the antigen-presenting cells (Osuga et al., 2011). 
Helper T cells include the Th1 cells, Th2 cells (Osuga et al., 2011), Th17 cells (Park et al., 
2009) and the regulatory T cells (Robertson et al., 2009). Subpopulations of T cells, including 
the regulatory T cells, will be discussed in detail in section 2.5.2.
 
1.5.2 IMMUNE CELL DYSREGULATION IN ENDOMETRIOSIS  
Immune cells differ in numbers and function in various body compartments in different 
phases of the menstrual cycle. These differences appear to facilitate the endometrium for 
embryo implantation and prevent certain reproductive pathologies (Johnson et al., 1999, El-
Hamarneh et al., 2013). Changes in the numbers and function of different immune cells 
during the normal menstrual cycle are summarised in Table 1.2. 
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Table 1.2. Immune cell population changes during the normal menstrual cycle.  
CELL 
TYPE 
MENSTRUAL CYCLE 
 
REFERENCES 
Endometrium 
Peripheral blood 
(PB) 
Natural Killer Cells (NKs) 
 
NUMBERS ↑ from proliferative to late 
secretory phase and ↓ after 
menstruation 
↑ in secretory phase 
compared to 
proliferative 
(Starkey et al., 1991, Yovel et al., 
2001, Lobo et al., 2004, Lee et al., 
2011) 
FUNCTION -↓ cytotoxicity in secretory 
phase  
-Remodel spiral arteries, 
secrete angiogenic and 
growth factors   
No change or ↑ in 
cytotoxicity in 
proliferative phase 
compared to secretory 
phase 
(Sulke et al., 1985, Ho et al., 1996, 
Yovel et al., 2001, Souza et al., 2001, 
Lobo et al., 2004, Dosiou and Giudice, 
2005, De Carolis et al., 2010, Lee et 
al., 2011) 
Macrophages 
 
NUMBERS -Stable in endometrium in 
proliferative and secretory 
phases 
-↑ from mid-menstrual 
phase with peak in post-
menstrual period  
Unknown (Braun et al., 2002, Berbic et al., 2009)  
FUNCTION -↑ Release of proteases help 
in degrading endometrium 
- Express adhesion and 
activation markers in 
proliferative phase, roles in 
endometrial regeneration  
Unknown 
 
 
 
(Arcuri et al., 2001, Lin et al., 2010, 
Thiruchelvam et al., 2013) 
Dendritic Cells (DCs) 
 
NUMBERS -Immature DCs ↑ 
throughout the menstrual 
cycle in basal layer  
-Mature DC numbers 
remain constant 
Unknown (King, 2000, Rieger et al., 2004, 
Schulke et al., 2008, Berbic and Fraser, 
2013) 
FUNCTION Unknown Unknown - 
T Lymphocytes 
 
NUMBERS ↓ from late proliferative to 
the late secretory phases 
 
↓ in mid- and late-
secretory phases 
compared to early 
secretory  
(Salamonsen and Lathbury, 2000, 
Flynn et al., 2000, Holtmeier and 
Kabelitz, 2005) 
FUNCTION Unknown Unknown - 
 
In women with endometriosis, immune cells change in numbers and function during the 
menstrual cycle compared to women without the disease (Gazvani and Templeton, 2002, 
Larosa et al., 2010). These differences and how they may contribute to endometriosis 
pathogenesis are summarised in Table 1.3.  
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Table 1.3. Alterations in immune cell populations in women with endometriosis compared to women without the disease. 
Cell Type Endometrium Lesions Peritoneal fluid Peripheral 
blood 
Implications for 
pathogenesis 
References 
Natural Killer Cells (NKs) 
NUMBERS ↓ in the mid-secretory 
phase 
↑ in the core 
lesions 
No change No change - ↓ cytotoxicity allows 
fragments to implant  
-NKs may be recruited to 
the lesions in attempt to 
inhibit growth  
  
(Viganò et al., 1991, Oosterlynck et 
al., 1992 , Iwasaki et al., 1993, 
Garzetti et al., 1993, Di Stefano et al., 
1994, Somigliana et al., 1996, Vinatier 
et al., 1996, Ganewatta et al., 2010, 
Sikora et al., 2011) 
FUNCTION ↓ cytotoxicity Unknown ↓ cytotoxicity ↓ cytotoxicity 
Macrophages 
NUMBERS ↑ in the proliferative and 
secretory phases, do not 
show expected ↑ during 
mid-menstruation  
Unknown Unknown Unknown -Disturbed apoptosis and 
removal of menstrual debris 
-Produce fibronectin which 
is involved in attachment of 
shed fragments  
-Haptoglobin impairs 
phagocytosis 
(Halme et al., 1984, Halme and 
Mathur, 1987, Zeller et al., 1987, 
Kauma et al., 1988, Vinatier et al., 
1996, Sharpe-Timms, 2001, Khan et 
al., 2004, Sharpe-Timms, 2005, Berbic 
et al., 2009, Lin et al., 2010)  
FUNCTION ↓ phagocytosis ↓ phagocytosis, 
produce 
haptoglobin  
↑ release of 
inflammatory 
cytokines 
Unknown 
Dendritic Cells (DCs) 
NUMBERS -↑ immature DCs in the 
proliferative phase  
-↓ mature DCs in the 
proliferative phase  
-↑ immature and 
mature DCs  
↓ mature DCs Unknown - Disturbed antigen 
presentation 
-↑ DC recruitment  in the 
lesions may be secondary to 
signalling by peritoneal 
micro-environment to get 
rid of shed debris 
(Schulke et al., 2009, Tariverdian et 
al., 2009)  
FUNCTION Unknown Unknown Unknown Unknown 
T Lymphocytes 
NUMBERS -↓ CD8+ cells and γδ-T 
cells and ↑Tregs in 
secretory phase  
-↑ CD8 cells 
-↓ in CD4:CD8 
ratio  
↑ CD4 and CD8 
cells 
↑ in CD4:CD8 
ratio  
-↓ cytotoxicity allows 
survival of shed fragments 
-Altered cytokine secretion 
by helper T cells may affect 
macrophage function 
(Steele et al., 1984, Gilmore et al., 
1992, Ota et al., 1996, Bulmer et al., 
1998, Szyllo et al., 2003, Gallinelli et 
al., 2004, Tariverdian et al., 2009, 
Berbic et al., 2010, Ganewatta et al., 
2010, Osuga et al., 2011)  
FUNCTION ↓ anti-inflammatory 
action 
↓ anti-
inflammatory 
cytokine 
production 
↓ anti-
inflammatory 
cytokine 
production 
↓ anti-
inflammatory 
cytokine 
production 
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Although data is lacking and the exact mechanisms are not well understood, defective 
immune surveillance in the endometrium, altered recruitment to lesions from systemic 
circulation (and vice versa) and inflammatory environment in the peritoneum may contribute 
to the pathogenesis of endometriosis. 
 
1.5.3 CYTOKINES AND GROWTH FACTORS  
Cytokines are cell-signalling protein molecules, which play a major role in the initiation and 
regulation of immune and inﬂammatory responses. Immune cell activation results in release 
of a cascade of cytokines from various cells (Iwabe et al., 2002). In endometriosis, cytokines 
are mainly produced by macrophages but lymphocytes, endometrial lesions and mesothelial 
cells of the peritoneum also release a variety of cytokines. Cytokines can be pro- or anti-
inflammatory, which recruit different cell types to the site of inﬂammation (Iwabe et al., 
2002).  
Cytokine secretion is altered in women with endometriosis in the endometrium, peritoneal 
lesions, peritoneal fluid and peripheral blood compared to women without the disease. Table 
1.4 summarises the expression and roles of key cytokines in endometriosis.  
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Table 1.4. Important cytokines and their possible roles in endometriosis. 
Cytokine Produced by Function/s Levels in 
endometriosis 
Possible role/s in 
endometriosis 
References 
Interleukin-1  Macrophages -Induces angiogenesis and 
expression of adhesion molecules 
-Pro-inflammatory  
Endometrium-
unchanged 
Lesions- ↑ 
Peritoneal fluid- 
↑/unchanged 
Blood -
unchanged 
-Promotes blood supply to 
lesions 
-Promotes endometrial cell  
peritoneal adhesion 
 
(Fakih et al., 1987, Mori et al., 1991, 
Keenan et al., 1995, Wang et al., 1995, 
Bedaiwy et al., 2002, Voronov et al., 
2003, Hudelist et al., 2005, Sokolov et 
al., 2005, Kalu et al., 2007, Guay et 
al., 2011) 
Interleukin-2 Helper T cells -Induce Fas-mediated apoptosis Endometrium- ↑ 
Lesions-
unknown 
Peritoneal fluid-
unchanged 
Blood-
unchanged 
↑ apoptosis of  lymphocytes 
in the endometrium that 
normally target shed 
fragments 
(Melioli et al., 1993, Keenan et al., 
1995, Hsu et al., 1997, Jaleco et al., 
2003, Sokolov et al., 2005) 
Interleukin -4 Th2, natural killer, 
γδ and mast cells 
Induces growth factor independent-1  Endometrium-
Unknown 
Lesions- ↑ 
Peritoneal fluid- 
↑ 
Blood- ↑ 
Stimulates proliferation of 
endometriotic stromal cells 
(Ho et al., 1996, Hsu et al., 1997, Zhu 
et al., 2002, Antsiferova et al., 2005, 
Ouyang et al., 2010) 
Interleukin -6 T cells and 
macrophages 
-↑ E-cadherin expression  
-Regulates ovarian hormone 
production, folliculogenesis and 
early stages of implantation 
  
Endometrium- ↑ 
Lesions- ↑ 
Peritoneal fluid- 
↑ 
Blood- ↑ 
-↑ adhesion of shed 
endometrial cells  
-Possible role in 
endometriosis-associated 
infertility by interfering 
with folliculogenesis and 
implantation 
(Tabibzadeh et al., 1989, Buyalos et 
al., 1992, Keenan et al., 1995, Akoum 
et al., 1996, Rier and Yeaman, 1997, 
Asgeirsson et al., 1998, Sokolov et al., 
2005) 
Interleukin -8 Macrophages Induces angiogenesis Endometrium- 
unknown 
Lesions- ↑ 
Peritoneal fluid- 
↑ 
Blood- ↑ 
Improves blood supply and 
proliferation within 
endometriotic lesions 
(Keenan et al., 1995, Kyama et al., 
2006, Kalu et al., 2007, Carmona et 
al., 2012) 
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Interleukin -10 Monocytes, Th2 
CD4+ cells, 
regulatory T cells 
and activated B cells 
Potent growth and differentiation 
factor for activated B cells 
Endometrium- 
unknown 
Lesions-
unknown 
Peritoneal fluid- 
unchanged 
Blood-
unchanged 
B cell function ↑ in 
endometriosis but exact role 
in disease pathogenesis 
unknown 
(Rousset et al., 1992, Ho et al., 1997) 
Interleukin -11 Endometrial stromal 
and epithelial cells 
-↑ lympho- & haemato-poiesis, 
placentation and decidualisation and 
facilitates implantation 
Endometrium- ↓ 
Lesions-
unknown 
Peritoneal fluid- 
unknown 
Blood- unknown 
Interferes with uterine 
receptivity and embryo 
implantation  
(Dimitriadis et al., 2006) 
Leukocyte 
migration 
Inhibitory 
Factor 
T and B 
lymphocytes 
-Promotes survival of primordial 
germ cells 
-Marker of embryo implantation  
Endometrium- ↓ 
Lesions-
unknown 
Peritoneal fluid- 
unknown 
Blood- unknown 
Interferes with uterine 
receptivity and embryo 
implantation 
(Hilton and Gough, 1991, Dimitriadis 
et al., 2006) 
Monocyte 
Chemotactic 
Protein 1 
 
 
Macrophages and 
endothelial cells 
Chemo-attractant, pro-inflammatory 
and activating factor for monocytes 
Endometrium-
unknown 
Lesions- ↑ 
Peritoneal fluid- 
↑ 
Blood- ↑ 
Recruitment and activation 
of peritoneal macrophages  
(Jolicoeur et al., 1998, Kalu et al., 
2007) 
Macrophage 
migration 
Inhibitory 
Factor 
 
Macrophages and 
dendritic cells 
Induces the expression of aromatase 
(enzyme for oestrogen synthesis) 
Endometrium- ↑ 
Lesions, 
peritoneal fluid 
and blood- 
unknown 
Oestrogen promotes growth 
of endometriotic lesions 
(Collette et al., 2006, Veillat et al., 
2012) 
Tumor Necrosis 
Factor-alpha 
 
Macrophages and 
lymphocytes 
-Regulate immune cells  
-Endometrial proliferation and 
shedding, 
-Pro-inflammatory  
Endometrium, 
lesions and 
blood-unknown 
Peritoneal fluid- 
↑ 
Promotes adhesion of 
endometrial fragments  
(Lebovic et al., 2000, Birt et al., 2013) 
20 
 
  
The development of endometriosis is a complex process, which includes disturbances in the 
numbers and function of immune cells and their released cytokines. Cytokine changes in 
endometriosis appear to increase angiogenesis, growth of lesions, inflammatory cell 
recruitment, adhesions and oestrogen production and interfere with embryo implantation and 
production of auto-antibodies against the endometrial cells. These changes may result in a 
failure of the immune system to clear shed and refluxed endometrial tissue and enhance 
development of the endometriotic lesions. 
 
1.6 CLINICAL ASPECTS 
1.6.1 SYMPTOMS 
Endometriosis commonly presents with pelvic pain and/or infertility.  
 
1.6.1.1 PELVIC PAIN 
Pain is an unpleasant sensory or emotional experience due to actual or potential tissue 
damage. In women evaluated for pelvic pain, 40-60 % are diagnosed with endometriosis 
(Murphy, 2002). Pelvic pain in endometriosis may be chronic or acute, in the form of 
dysmenorrhea (pain during menstruation), dyspareunia (painful sexual activity) and 
dyschezia (pain during defecation). Pelvic pain can be cyclic or acyclic. In endometriosis,  
90 % of women suffer from dysmenorrhoea, 42 % from deep dyspareunia and 39 % from 
non-menstrual pelvic pain (Jamieson and Steege, 1996). Although endometriosis is associated 
with pelvic pain, the mechanisms of pain in this disease are not well understood but likely 
include the nociceptive, inflammatory or neuropathic pathways (Jamieson and Steege, 1996, 
Howard, 2003, Howard, 2009).   
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1.6.1.2 INFERTILITY 
Infertility can be the only presenting symptom of endometriosis (Murphy, 2002). 
Endometriosis is present in 25-40 % of infertile women (Ozkan et al., 2008) and 30-50 % of 
women diagnosed with endometriosis present with infertility (Ajossa et al., 1994). 
Endometriosis-associated infertility will be discussed in detail in the second chapter of this 
literature review (section 2.3).  
 
1.6.2 DIAGNOSIS 
The gold standard for diagnosing endometriosis is visualisation of the abdominal and pelvic 
viscera under general anaesthesia by diagnostic laparoscopy (Kennedy et al., 2005). 
Laparoscopy involves keyhole surgery through small abdominal incisions and use of a 
camera to visualise the pelvic cavity. Inspection of the endometriotic implants and 
endometriomas at laparoscopy is used in conjunction with confirmation by histological 
examination (Murphy, 2002).    
Development of an accurate non-invasive diagnostic method for endometriosis is highly 
desirable. Imaging techniques like trans-vaginal ultrasound (TVS) and magnetic resonance 
imaging (MRI) have roles in diagnosing ovarian and deep lesions (Kennedy et al., 2005). 
Diagnostic tests using serum bio-markers such as IL-6, IL-8, CA-125, anti-transferrin and 
anti-2HS glycoprotein antibodies (Pillai et al., 1996, Mathur et al., 1998, Velasco et al., 2010, 
May et al., 2010, Somigliana et al., 2010) or endometrial biopsy (for example, detection of 
nerve fibres) have been explored (Al-Jefout et al., 2004), however, no method suitable for 
routine clinical practice has been identified yet (Somigliana et al., 2010).  
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1.6.3 TREATMENT  
Treatment options for endometriosis depend on the severity of the disease and include 
medical and surgical therapy, either alone or in combination. Management of endometriosis 
should be individualised depending on the desired treatment outcome like relief from pain, 
preventing recurrence or treatment of infertility (Ozkan and Arici, 2009). 
 
1.6.3.1 MEDICAL 
Medical options include analgesia, such as over the counter pain killers (for example, non-
steroidal anti-inflammatory drugs), and the hormonal therapies, such as oral contraceptive 
pills (OCPs), progestogens (oral, injectable, sub-dermal implants or intra-uterine device) and 
gonadotropin-releasing hormone (GnRH) analogues (Olive and Pritts, 2001, Olive et al., 
2003, Ozawa et al., 2006). All hormonal options in general aim to reduce oestrogen 
dominance of the disease and by inducing an amenorrhoeic state, arrest the growth of 
endometriotic lesions (Ozkan and Arici, 2009). All hormonal agents have almost the same 
efficacy, although they differ in their side effect profile (Ozkan and Arici, 2009). Medical 
treatment generally improves pain scores for endometriosis-related pain (Ailawadi et al., 
2004, Batzer, 2006, Abushahin et al., 2011). Medical therapy is not suitable if fertility is 
desired, as most of the options are contraceptive (Olive and Pritts, 2001, Ozkan and Arici, 
2009). 
1.6.3.2 SURGICAL 
Endometriosis surgery aims to remove all the apparent lesions in the pelvis and abdomen and 
restore normal anatomy, either through the laparoscope or via laparotomy with access to the 
abdomino-pelvic cavity through a wide incision (Hershlag and Markovitz, 2005). Surgical 
approaches include conservative options such as excision of lesions, destruction by electro-
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cautery or lasers through to radical surgery involving removal of uterus (hysterectomy) 
and/or bilateral fallopian tubes and ovaries (salpingo-oophorectomy) and deep resection of 
bowel and bladder lesions (Kim and Adamson, 1999, Osuga et al., 2002).  Cautery can be 
used to ablate the peritoneal lesions (Valle and Sciarra, 2003) but it is ineffective in clearing 
DIE and can cause injury to the underlying structures such as vessels and the ureters 
(Milingos et al., 2003, Valle and Sciarra, 2003, Abbott et al., 2003). Therefore, surgical 
excision is the preferred method for removal of endometriosis, particularly DIE (Milingos et 
al., 2003). Laparoscopy and laparotomy are equally effective in treating endometriosis but 
laparoscopy has the added advantage of better visualisation, less tissue trauma and faster 
recovery (Vercellini et al., 2010). 
 
Although both surgical and medical treatments can effectively relieve pain associated with 
endometriosis, recurrence rates remain high (Olive and Pritts, 2001, Olive et al., 2003, Ozawa 
et al., 2006). Following conservative surgery, endometriosis has a recurrence rate of 20-40 % 
within five years. Whether endometriosis will recur post-operatively depends on how severe 
the disease was at the time of surgery and how completely the lesions were removed 
(Vercellini et al., 2010).  
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CHAPTER 2: ENDOMETRIOSIS-ASSOCIATED INFERTILITY AND 
REGULATORY T CELLS 
 
2.1 INTRODUCTION 
As touched upon in chapter 1, women with endometriosis may present with infertility. 
Immunological disturbances in endometriosis may adversely affect the fertility of these 
women. Regulatory T cells are a sub-population of T cells with immuno-suppressive 
properties, which are crucial for female fertility and appear to be dysregulated in 
endometriosis. In this chapter, female infertility and its associations with immune alterations, 
particularly those of Tregs, will be discussed. 
 
2.1.1 NORMAL CONCEPTION AND IMPLANTATION 
In normal conception, fertilisation occurs in the fallopian tube, the embryo travels to the 
uterus and implants in the endometrium in the mid-secretory phase of the menstrual cycle 
(the ‘implantation window’) (Lee et al., 2011). Since half of the fetal antigens are of paternal 
origin, successful implantation depends on maternal immune tolerance of the fetus (feto-
maternal tolerance) (Aagaard-Tillery et al., 2006). The immunological relationship between 
mother and fetus is complex. Endometrial function and embryo-endometrial interaction 
involve multiple immune and molecular signalling cascades (Simon et al., 1995). The 
endometrial immune cells and cytokines are altered in the peri-implantation period to 
establish and maintain pregnancy through various mechanisms, which are not yet fully 
understood.
 
 
 
25 
 
 
 
2.2 INFERTILITY 
The World Health Organisation (WHO) defines infertility as the inability of a sexually active 
couple, having coitus at least three times per month, to conceive in one year while not using 
any contraception (Hamada et al., 2012). Infertility occurs in around 15 % of couples (Kokcu 
et al., 2012). Infertility may be due to male or female factors or a combination of both. The 
main causes for female infertility, which may be associated with ovarian, tubal or 
endometrial immune disturbances, are absence of ovulation (anovulation), anatomical and/or 
functional abnormalities in the fallopian tubes (tubal factors) and endometriosis (Muse and 
Wilson, 1982, Mardh, 2004, Kokcu et al., 2012, Samsami Dehaghani et al., 2013). In male 
infertility, sperm numbers and/or function are altered that may be secondary to genetic or 
inherited diseases, specific abnormalities in the Y chromosome, anatomical abnormalities, 
hormonal disturbances, infections, chemicals, drugs and tumours (Nwabuisi and Onile, 2001, 
Costabile and Spevak, 2001, Poongothai et al., 2009, Ahmed et al., 2010).  
 
2.2.1 IMMUNE ASPECTS OF FEMALE INFERTILITY 
As mentioned in section 2.1.1, the endometrium ‘tolerates’ the fetus by immune mechanisms 
(Aagaard-Tillery et al., 2006). Disturbances in the numbers and/or function of the 
endometrial immune cells and their produced cytokines during the ‘implantation window’ 
may result in difficulty conceiving and pregnancy failure (Lee et al., 2011). Immune cell 
disturbances implicated in female infertility are summarised in Table 2.1. 
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Table 2.1. Immune disturbances in female infertility. 
 
Cell type Roles in normal embryo 
implantation and 
development 
Levels in 
infertility 
Possible roles in 
infertility 
References 
Dendritic 
Cells 
-↑ in decidua 
-Pro-apoptotic, regulate 
angiogenesis and tissue 
remodelling and enhance 
development of Tregs 
↑ in peritoneal 
fluid  
Stimulate 
autoimmune 
response against 
oocyte 
(Błaszkowska et al., 
2001, Plaks et al., 2008, 
Pollard, 2008) 
Macrophages -Release pro-inflammatory 
cytokines 
-Enhance tissue and vascular 
remodelling and immune 
tolerance 
↑ in peritoneal 
fluid and 
fallopian tubes 
Phagocytosis of 
sperm 
(Haney et al., 1983) 
Natural 
Killer cells  
-Secrete cytokines, help in 
migration of trophoblasts 
into spiral arteries and 
increase blood flow to fetus 
-Promote fetal-tolerance by 
regulating pro-inflammatory 
cells 
Either no 
change or ↓ 
numbers in 
endometrium 
Targeting of 
trophoblast cells 
can result in 
fetal rejection 
(Moffett et al., 2004, 
Vujisić et al., 2004, 
Hanna et al., 2006, 
Manaster and 
Mandelboim, 2008, 
Kumar and Medhi, 
2008, Manaster and 
Mandelboim, 2010, 
Tang et al., 2011, Fu et 
al., 2013) 
T Cells Th1 – Numbers ↓ but 
cytokine production ↑, 
(Tumor Necrosis Factor-α 
and interferon-γ in 1st  
trimester) 
-Pro-inflammatory 
-Facilitate embryo 
implantation by ↑ 
endometrial invasion  
Th2 - Numbers ↓ but 
cytokine production ↑, 
(interleukin-4 and 10 in 2
nd
 
trimester) 
-Anti-inflammatory 
-Facilitate fetal growth and 
development 
No change in 
peritoneal fluid 
and blood 
Unknown (Veenstra et al., 2003, 
Vujisić et al., 2004, 
Mor et al., 2011) 
B Cells -Roles in folliculogenesis 
uncertain 
- Facilitate implantation, 
placentation, and early 
embryonic development 
Immunoglobulin 
A & M ↓ in 
peritoneal fluid 
and blood 
-Anti-sperm, 
anti-follicle 
stimulating 
hormone & anti-
phospholipid 
antibodies ↑ in 
blood and 
cervical mucous 
Decreased sperm 
motility and 
impaired 
folliculogenesis, 
fertilisation and 
implantation 
(Marshburn and Kutteh, 
1994, Hjort, 1999, 
Backos et al., 2002, 
Bohring and Krause, 
2003, Vujisić et al., 
2004, Bohring and 
Krause, 2005, Carp and 
Shoenfeld, 2007, 
Nagamatsu and Schust, 
2010) 
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In summary, immune alterations can contribute to unexplained female infertility by 
mechanisms such as disturbed ovulation, folliculogenesis and implantation and phagocytosis 
of sperm. 
 
2.3 ENDOMETRIOSIS-ASSOCIATED INFERTILITY 
The prevalence of infertility is up to 50 % in women with endometriosis, much higher than in 
women without the disease in whom it is 5-10 % (D'Hooghe et al., 2003, Koch et al., 2012, 
Stilley et al., 2012). In addition, about 25–50 % of infertile women have endometriosis 
compared to 0.5-5 % of fertile women (Ozkan et al., 2008, Bulletti et al., 2010, Falcone and 
Lebovic, 2011). 
 
2.3.1 MECHANISMS  
It is well established that extensive endometriosis can distort the pelvic anatomy that may 
result in infertility. However, so called milder forms of the disease may also result in 
infertility (Falcone and Lebovic, 2011). Therefore, anatomical abnormalities alone are not 
responsible for endometriosis-associated infertility, suggesting other mechanisms like 
hormonal, cytokine or immunological abnormalities may have roles (Gupta et al., 2008, 
Holoch and Lessey, 2010). A range of processes implicated in endometriosis-associated 
infertility are reviewed below. 
 
2.3.1.1 FOLLICULOGENESIS AND OVULATION  
In endometriosis, there are pro-inflammatory changes in the follicular fluid which may 
adversely affect the follicular growth and function (Garrido et al., 2000). Increased 
interleukin-6 (IL-6) and decreased vascular endothelial growth factor levels in follicular fluid 
in endometriosis compared to women with unexplained infertility result in slower growth rate 
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of ovarian follicles and reduced size and vascularisation of the dominant follicle, respectively 
(Pellicer et al., 1998, Cahill et al., 2000, Garrido et al., 2000, Trinder and Cahill, 2002, 
Yoshida et al., 2004). In endometriosis, elevated numbers of macrophages and leukocytes in 
follicular and peritoneal fluid produce reactive oxygen species, which interfere with ovarian 
steroidogenesis and ovulation (Das et al., 2006). Reactive oxygen species are chemically 
reactive molecules concerned with cell signalling and if increased in concentration, they 
cause cellular damage (Van et al., 2002). Altered folliculogenesis may contribute to ovulatory 
disturbances such as reduced circulating concentrations of oestradiol in the pre-ovulatory 
phase, delayed LH surge, anovulation or delayed release of oocyte from ovary (Trinder and 
Cahill, 2002). 
 
2.3.1.2 OOCYTE QUALITY AND FUNCTION  
Alterations within follicles may result in oocytes and embryos of lower quality in women 
with endometriosis (Pellicer et al., 2000). In endometriosis, the number of oocytes retrieved 
for in-vitro fertilisation (IVF), embryo cleavage rates and pregnancy rates are markedly 
decreased compared to women without the disease (Du et al., 2013). In addition, evidence 
suggests lower pregnancy rates with oocytes derived from women with endometriosis when 
donated to controls compared to oocytes derived from women without the disease (Simon et 
al., 1994). Reduced oestrogen levels in the follicular fluid (Wunder et al., 2005) may be the 
underlying cause of low quality and number of oocytes in endometriosis as oocyte quality 
and number is dependent on the follicular fluid oestrogen levels (Díaz et al., 2008). In 
addition, elevated levels of prostaglandin E2, a fatty acid derivative and regulator of 
oestrogen producing enzyme aromatase, in the follicular fluid and IL-10 in the peritoneal 
fluid in endometriosis may inhibit oocyte maturation by interfering with granulosa cell 
development (Punnonen et al., 1996, Noble et al., 1997, Díaz et al., 2008, Lin et al., 2012, Du 
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et al., 2013). Brizek and co-workers reported micro-tubular and chromosomal abnormalities 
in oocytes from women with endometriosis (Brizek et al., 1995). Although these findings are 
confirmed in mouse and bovine oocytes grown in-vitro in follicular fluid from infertile 
women with endometriosis (Mansour et al., 2009, Da Broi et al., 2014), more recent studies 
on human oocytes fail to support such abnormalities (Barcelos et al., 2008, Dib et al., 2013).  
 
2.3.1.3 SPERM FUNCTION 
In endometriosis, sperms available for fertilisation decrease in numbers due to their increased 
binding to the epithelium in the ampulla of fallopian tubes (Reeve et al., 2005). In addition, in 
women with endometriosis the environment within the reproductive tract increases sperm 
DNA fragmentation and  membrane permeability, loss of membrane integrity, spermatic 
enzyme inactivation (Agarwal et al., 2006) and decreased sperm-oocyte fusion (Baker and 
Aitken, 2004). Elevated levels of reactive oxygen species in the peritoneal fluid in 
endometriosis may cause DNA fragmentation and other damage to the sperm cells (Van et 
al., 2002). In addition, increased peritoneal fluid levels of cytokines such as IL-6, Regulated 
on Activation, T cell Expressed and Secreted (RANTES) and Tumor Necrosis Factor-alpha 
reduce sperm motility, fertilising capacity, sperm counts and sperm-oocyte binding by 
enhanced reactive oxygen species production, respectively (Punnonen et al., 1996, Said et al., 
2005, Bersinger et al., 2006, Barbonetti et al., 2008).
 
2.3.1.4 FERTILISATION AND IMPLANTATION 
Lower pregnancy rates in women with endometriosis may largely be accounted for by 
abnormalities of fertilisation and/or implantation in the endometrium, resulting in failure of 
pregnancy establishment (Kao et al., 2003, Dechaud et al., 2009). Peritoneal fluid in 
endometriosis inhibits oocyte-sperm binding (Faber et al., 2001) due to altered cytokine and 
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growth factor balance (Vassiliadis et al., 2005). Possible mechanisms affecting implantation 
in endometriosis may include endometrial anomalies in endometriosis as reviewed in section 
1.4.2.3 such as progesterone resistance with luteal phase deficiency, altered immune 
environment, altered expression of genes involved in embryonic attachment and apoptotic 
responses (Kao et al., 2003) and reduced or absent expression of the adhesion molecule 
integrin which facilitates implantation (Lessey et al., 1994). Collectively, these mechanisms 
create a hostile endometrial environment for the embryo.  
 
2.3.1.5 PERITONEAL ENVIRONMENT  
Peritoneal environment is altered in women with endometriosis, which may contribute to 
infertility in these women (Iwabe et al., 2002). Fertility may be affected in endometriosis by 
disruption of the pelvic anatomy and angiogenic and immunological alterations (Iwabe et al., 
2002). While pelvic adhesions usually affect fertility in advanced stages of the disease, 
adhesion formation is mainly dependent on pro-inflammatory and angiogenesis-related 
cytokines (such as IL-6 and IL-8) in the peritoneal fluid (Barcz et al., 2012, Tagashira et al., 
2009). Moreover, immune alterations in the peritoneal cavity may be the main culprit in the 
milder forms of the disease (Barcz et al., 2012). Immune cell populations (predominantly 
macrophages) and their released cytokines are altered in the peritoneal cavity of women with 
endometriosis compared to controls, which may adversely affect a variety of reproductive 
functions (Hou et al., 2009, Liu et al., 2000). Tubal macrophages increase in numbers 
secondary to peritoneal fluid macrophages in endometriosis (Haney et al., 1983). It is also 
suggested that elevated concentrations of apoptosis-inducing Fas-ligand in the peritoneal 
fluid enhance apoptosis of the granulosa cells of the ovarian follicle and interfere with quality 
of the oocyte (Garcia-Velasco et al., 2002). Increased embryo-toxicity of oocytes can be 
another mechanism of reduced fertility in women with endometriosis, which has been 
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demonstrated in mouse oocytes developed in human peritoneal fluid (Gomez-Torres et al., 
2002). 
In summary, fertility in endometriosis appears to be negatively affected at almost every stage 
of ovulation and establishment of pregnancy. Most of these mechanisms are related to 
immunological disturbances. Processes that are affected include folliculogenesis, ovulation, 
oocyte and sperm function, fertilisation, implantation and blastocyst development (Gupta et 
al., 2008). 
 
2.4 ARTIFICIAL REPRODUCTIVE TECHNIQUES IN ENDOMETRIOSIS-
ASSOCIATED INFERTILITY 
Assisted reproductive technology (ART) is the application of laboratory or clinical 
techniques to gametes (human egg or sperm) and/or embryos for the purposes of 
reproduction. The most effective treatment for endometriosis-associated infertility is IVF 
(Senapati and Barnhart, 2011). As discussed in section 2.3, endometriosis affects fertility by 
various mechanisms. IVF can overcome several of these mechanisms such as disturbances of 
ovulation, defects of the fallopian tubes and tubal transport, sperm function and quality of 
gametes and embryos to some extent. However, disturbances in the eutopic endometrium and 
implantation may not be overcome by IVF.  
 
Overall, women with endometriosis have lower pregnancy rates after IVF than those with 
other causes of infertility (Senapati and Barnhart, 2011). In infertile women without 
endometriosis, pregnancy rates are around 34 % after each IVF cycle (Senapati and Barnhart, 
2011). A large meta-analysis has suggested that pregnancy rates after IVF are reduced to half 
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in women with endometriosis compared to those without (Meldrum et al., 1998, Barnhart et 
al., 2002). 
 
Intra-cytoplasmic sperm injection (ICSI) is an advanced form of ART in which a single 
sperm is injected directly into an egg (Sherins et al., 1995). ICSI offers the added advantage 
of higher fertilisation rates. It is, therefore, a better treatment option than conventional IVF in 
endometriosis-associated infertility complicated with male factor infertility (Mínguez et al., 
1997, Bukulmez et al., 2001, Ballester et al., 2012, Komsky-Elbaz et al., 2013). But like IVF, 
ICSI may not alter the endometrial microenvironment to improve implantation. 
 
In summary, current methods of ART improve chances of pregnancy and live birth rates in 
women with endometriosis-associated infertility but have limitations. It is highly desirable to 
develop better treatment options to increase chances of conception in infertile women with 
endometriosis.  
2.5 T CELL LINEAGE 
As discussed in section 2.3, a range of factors may contribute to endometriosis-associated 
infertility. Immune aspects, including immune cells and cytokines, are altered in the disease 
and may have a role in its pathophysiology and associated infertility (Holoch and Lessey, 
2010). T cells are a group of immune cells which perform a wide range of functions. Their 
developmental pathway, subgroups, functions and how they may contribute to endometriosis-
associated infertility will be discussed below.  
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2.5.1 T CELL DEVELOPMENT AND ANTIGEN RECOGNITION 
T cells develop in the thymus from T cell progenitors (Bhandoola et al., 2003). Mature T 
cells express specific surface-markers such as T cell receptors (TCRs), CD4 and CD8. 
Progenitor T cells are CD4 and CD8 negative. Once they start to be expressed on T cells in 
the thymus, these cells are referred to as double positive thymocytes. At this stage, central 
tolerance mechanisms operate to ensure T cells that are capable of reacting against foreign-
antigens are selected for further differentiation (positive selection). Those double positive 
cells which may initiate an auto-immune response are eliminated before they reach systemic 
circulation (negative selection) (Xiong and Raulet, 2007). Positive selection of double 
positive thymocytes allows their survival and interaction with self-major histocompatibility 
complex (MHC). MHC is a cell-surface molecule which mediates interaction between 
leukocytes and other cells. Depending on their structure, there are two classes of MHC (I and 
II). Double positive cells that interact well with MHC class II molecules will eventually 
become single positive CD4
+
 cells, while thymocytes that interact well with MHC class I 
molecules mature into single positive CD8
+
 cells. Double positive thymocytes that interact 
with MHC molecules either too strongly or too weekly die by neglect or programmed cell 
death (apoptosis), respectively (Xing and Hogquist, 2012).  
 
Negative selection removes the thymocytes that interact too strongly with self-antigens and 
may cause auto-immunity. Negative selection occurs by clonal deletion, receptor editing or 
clonal diversion, ensuring tolerance of self-antigens (self-tolerance). Clonal deletion occurs 
during the fetal life when immunocytes with self-antigen reactivity are deleted (Palmer, 2003, 
Baldwin and Hogquist, 2007). Receptor editing changes TCR specificity by secondary gene 
rearrangements at the TCR loci to prevent auto-reactivity (Wang et al., 1998, Holman et al., 
2003). Clonal diversion occurs when thymocytes get signals through their auto-reactive TCR 
34 
 
 
 
but are not able to receive co-stimulatory signals. In contrast to clonal deletion that ‘deletes’ 
self-reactive cells, clonal diversion imparts suppressive or regulatory function to self-reactive 
cells (Xing and Hogquist, 2012) but cells derived from clonal diversion are non-responsive 
(clonal anergy). Anergy can be clonal or adaptive. Clonal anergy is a growth-arrest state, 
which develops in the thymus and may be reversed by an interleukin-2-rich micro-
environment. Adaptive anergy can be central (develop in the thymus) or peripheral and 
represent generalised inhibition of further proliferation of T cells at varying stages of 
development in persistent presence of a specific antigen. Adaptive anergy reverses if the 
particular antigen is removed (Schwartz, 2003, Baldwin and Hogquist, 2007). 
 
The generation of Tregs in the thymus begins as a result of an altered negative selection 
process. Naïve T cells differentiate to Tregs when their TCR/antigen affinity is just weaker 
than that needed for negative selection but at the extremity of threshold for positive selection 
(Jordan et al., 2001) (Figure 2.1). Regulatory cells which receive co-stimulatory signals (by 
CD28) and CD86 expression acquire Foxp3 in the thymus (Chatenoud and Bach, 2006).  
 
 
Figure 2.1. Regulatory T cells are selected in the thymus when the avidity of their T cell receptors for self-
major histocompatibility complex is lower than the threshold for negative selection by apoptosis but 
higher than the threshold for positive selection of T cells (Guerin et al., 2009).  
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After positive and negative selection, remaining thymocytes mature as naïve T cells (Wang et 
al., 1998, Buch et al., 2002, Holman et al., 2003). Naïve T cells in the thymus are activated 
after binding with antigen-MHC complexes, facilitated by certain co-receptors (CD4 for 
helper and CD8 for cytotoxic T cells) (Davis and Bjorkman, 1998). Naïve T cells then leave 
the thymus (Fessler et al., 2013).
 
Central tolerance mechanisms in the thymus cannot remove all self-responsive T cells as not 
all antigens are expressed in the thymus (Xing and Hogquist, 2012). To ensure further self-
tolerance, when T cells first encounter antigens after maturing and entering the periphery, 
they become functionally anergic to TCR signals (adaptive anergy) (Xing and Hogquist, 
2012). Once in the periphery, T cells are presented antigens by antigen-presenting cells 
through MHC I and II (Burster, 2013). T cells in the periphery differentiate into T cell 
subtypes, which perform different functions, depending mainly on the cytokine micro-
environment and antigenic type (Fietta and Delsante, 2009, Fessler et al., 2013). 
 
2.5.2 SUB-POPULATIONS OF T CELLS 
Classically, T cell sub-populations include cytotoxic, gamma-delta (γδ), helper (Th), memory 
and natural killer T (NKT) cells (Zheng et al., 2004, Wang et al., 2006) (Table 2.2).  
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Table 2.2. Classification of T cells. 
 
Cell Type       Function Sub-classes References 
Cytotoxic 
(CD8+) 
-Kill tumour or virus 
infected cells 
-Release cytotoxins 
- 
 
(Milstein et al., 2011) 
Gamma 
delta (γδ) 
-First line of defence in 
epithelial cell-rich 
compartments 
-Produce cytokines 
-Potent cytotoxic activity 
- 
 
(Kabelitz and Wesch, 2003, 
Holtmeier and Kabelitz, 2005) 
Helper 
(CD4+) 
-Release cytokines 
-Help B cells to produce 
antibodies 
-Activate CD8+ cells 
- ↑ bactericidal activity 
of phagocytes  
Helper type I (Th1) 
-Produce interferon-γ, 
interleukin-2, and tumor 
necrosis factor- β  
-Activate macrophages 
and phagocytosis 
(Romagnani, 1999 , Zheng et al., 
2004, Wang et al., 2006, 
Sakaguchi, 2006, Rautajoki et al., 
2008, Korn et al., 2009) 
Helper type II (Th2) 
-Release interleukin-4, 5, 
9 and 13 
-Activate mast cells and 
eosinophils 
-Induce B lymphocytes 
-Production of 
Immunoglobulin E 
Helper type 17 (Th17) 
-Produce interleukin-17 
and 21  
-Pro-inflammatory  
-Recruit neutrophils to 
sites of inflammation 
Regulatory T cells 
(Tregs) 
-Control and suppress 
range of immune 
functions 
Memory T 
cells 
-Provide memory against 
past exposure  
-Quickly expand after re-
exposure to antigen 
- (Akbar et al., 1988) 
Natural 
killer T 
(NKT) cells 
-Helper and cytotoxic 
functions 
-Produce cytokines and 
bridge gap between innate 
and adaptive immunity 
- 
 
(Van Kaer and Joyce, 2005, 
Tupin et al., 2007) 
 
2.6 REGULATORY T CELLS 
Regulatory T cells (Tregs) were first described in 1972 when T cells with suppressive 
properties were identified and termed ‘suppressive’ cells (Gershon et al., 1972). However, 
their existence as a distinct T cell sub-population remained controversial until the mid-1990s 
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(Green and Webb, 1993). They are now considered a separate specialised T cell sub-group 
(Sakaguchi et al., 1995, Burzyn et al., 2013). 
 
2.6.1 LINEAGE OF REGULATORY T CELLS 
Based on origin, protein expression, mechanism of action and function, there are two classes 
of Tregs: natural/naïve/professional (nTregs) and induced/adaptive/memory (iTregs). 
Recently, other T cells such as γδ cells, natural killer T cells and double negative also thought 
to have regulatory functions have been proposed to be included in the regulatory T cell group 
(Fessler et al., 2013). However, their immunosuppressive roles are less well known (Guerin 
et al., 2009, Raffin et al., 2013) and in this literature review, Tregs will be restricted to nTregs 
and iTregs only.  
 
Naturally occuring Tregs originate from the thymus as CD4+CD25+Foxp3+ cells (Figure 
2.2) (Chatenoud and Bach, 2006). Naturally ocurring Tregs are long-lived, foreign-antigen 
non-specific and directly control other T cells by T cell-T cell interaction (Suciu-Foca et al., 
2003, Tanaka and Sakaguchi, 2005). As discussed in section 2.5.1 and illustrated in Figure 
2.1, cells destined to become nTregs are different from other T cells as they interact with self-
antigens neither weakly nor too strongly to protect themselves from negative selection 
(Maggi et al., 2005, Xing and Hogquist, 2012). In the thymus, T cells with highly reactive 
TCRs are rescued from deletion by cytokines or a second TCR and go on to become 
regulatory T cells (Tregs) with suppressive functions (Xing and Hogquist, 2012). 
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Figure 2.2. Developmental pathways and markers of Treg sub-groups. Natural Tregs use cytokines to 
exert their action. Induced Tregs can be generated from T cell precursors. Naïve T cells become Foxp3-
Tr1 cells or Foxp3+ Th3 cells by cytokines secreted by antigen-presenting cells. TEC= thymic epithelial 
cell; Tconv= conventional T cell; APC=antigen presenting cell & DC= dendritic cell Adapted from 
(Workman et al., 2009). 
Naturally occurring Tregs differ from iTregs in many aspects, which are summarised in Table 
2.3. However, the features which differentiate the two groups are not universally accepted 
(Lin et al., 2013). 
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Table 2.3. Differences between regulatory T cell subsets. 
 Natural Tregs Induced Tregs References 
Generation Thymus Gut-associated lymphoid tissue, spleen, 
lymph nodes & inflamed tissue 
(Curotto et 
al., 2004) 
Co-stimulation 
requirement 
CD28 Cytotoxic T lymphocyte-associated 
protein-4 
(Curotto et 
al., 2004) 
Cytokine 
requirement 
Tumor growth factor-beta 
and interleukin-2 or 15 
Tumor growth factor-beta and 
interleukin-2 
(Curotto et 
al., 2004) 
Specificity Self Allergens, commensal bacteria, neo-
antigens (tumor), allo-antigens (fetus) 
(Curotto et 
al., 2004) 
Life span Longer than iTregs but 
unstable in inflammatory 
conditions  
Short-lived but remain stable in 
inflammatory conditions 
(Yadav et al., 
2013) 
Foxp3 Positive May be positive (Th3) or negative (Tr1) (Curotto et 
al., 2004) 
Adapted from (Curotto and Lafaille, 2009). 
 
Induced Tregs (CD4+CD25+) develop from mature CD4+ conventional T cells outside of the 
thymus (Haribhai et al., 2011) after stimulation by cognate antigens (which can stimulate 
nTreg and iTregs) and immune-regulatory cytokines (such as TGF-β, IL-10, and IL-4) 
(Seddon and Mason, 1999, Maggi et al., 2005, Chatenoud and Bach, 2006, Akbar et al., 2007, 
Peterson, 2012). Two main subsets of iTregs, based on the cytokines that cause their 
induction and are then produced by iTreg subsets, include Foxp3- type 1 regulatory T cells 
(Tr1) that are induced by IL-10 and Foxp3+ T helper 3 (Th3), which are induced by TGFβ 
(Figure 2.2) (Sakaguchi et al., 1995, Groux et al., 1997, Jonuleit and Schmitt, 2003, 
Workman et al., 2009, Kushwah and Hu, 2011 , Peterson, 2012, Duhen et al., 2012, Lin et al., 
2013). Peripheral generation of iTregs produces suppressive cells with affinity for antigens 
not expressed in the thymus (Guerin et al., 2009). Tissue-specific antigen recognition by 
iTregs is important to protect against foreign antigens (Samy et al., 2006) (Figure 2.2). 
 
2.6.2 MARKERS 
Tregs are identified on the basis of expression of various cell surface and intracellular 
markers which are detailed in Table 2.4 (Figure 2.2). Despite a long list of available markers, 
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it has not been possible to accurately distinguish Tregs from other T cells or iTregs from 
nTregs due to low specificity and variable expression of markers (Tran et al., 2007).  
 
Table 2.4. Treg markers in humans. 
Markers Structure Expressed by References 
Aiolos Intracellular transcription factor iTregs (Raffin et al., 2013) 
CCR4 
(CD194) 
Cell surface protein receptor nTregs, iTregs (Kevin et al., 2010) 
CCR6 
(CD196) 
Cell surface protein receptor iTregs (Chen et al., 2003, 
Kitamura et al., 2010) 
CCR7 Cell surface protein receptor  iTregs (Raffin et al., 2013) 
CD25  Trans-membrane protein Anergic & activated nTregs, 
iTregs 
(Scotto et al., 2004) 
CD45RB Trans-membrane protein  Anergic nTregs (Scotto et al., 2004) 
CD73 Trans-membrane protein Higher expression in nTregs than 
iTregs 
(Lin et al., 2013) 
CD95  Trans-membrane protein nTregs,  iTregs (Scotto et al., 2004) 
CD127 Trans-membrane protein Absent on Treg (expression 
inversely correlates with 
suppressive function of Foxp3+ 
cells) 
(Scotto et al., 2004 ) 
CTLA-4 
(CD152) 
Cell surface protein receptor Anergic and activated nTregs, 
iTregs 
(Scotto et al., 2004) 
CXCR3 G protein-coupled receptor iTregs (Hoerning et al., 2011) 
Eos Intracellular transcription factor  nTregs (Raffin et al., 2013) 
Foxp3 Intracellular transcription factor 
(master regulator of Treg 
development & function) 
nTregs, Th3 (Korn et al., 2009) 
GITR Cell surface protein receptor Anergic and activated nTregs, 
iTregs 
(Scotto et al., 2004) 
Helios 
(Ikzf2) 
Intracellular transcription factor Higher expression in nTregs than 
iTregs 
(Raffin et al., 2013) 
IL-1R1  Cell surface protein receptor  iTregs (Raffin et al., 2013) 
LAG-3 
(CD223) 
Cell surface protein nTregs, Th3 (Scotto et al., 2004) 
Nrp-1  
 
Cell surface protein receptor Higher expression in nTregs 
compared to iTregs 
(Hey-Cunningham et 
al., 2013, Lim et al., 
2006) 
Pdcd-1 Cell surface protein Higher expression in nTregs 
compared to iTregs 
(Lin et al., 2013) 
CTLA-4= Cytotoxic T lymphocyte-associated protein- 4, CXCR3= Chemokine receptor 3, GITR= 
Glucocorticoid induced tumour necrosis factor receptor, IL-1R1= Interleukin receptor 1 type 1, LAG-3 = 
Lymphocyte activation gene-3, Nrp-1= Neuropilin-1, Pdcd-1= Programmed cell death-1. 
The combination of staining for CD4, CD25 and CD127 is a common and reliable method for 
identification of Tregs which are CD4+CD25+CD127
-/dim 
(Liu et al., 2006, Seddiki et al., 
2006). Forkhead box p3 (Foxp3) has been the best known single maker for identification of 
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Tregs (Giatromanolaki et al., 2008). It is now realised that Foxp3 alone may not be an ideal 
marker to recognise Tregs as human Foxp3 is also up-regulated in activated T cells without 
suppressive functions (such as inducible CD8+ cells) (Chen et al., 2003, Raffin et al., 2013). 
It has recently been suggested that neuropilin-1 and Helios expression in conjunction may 
provide a superior way to identify Tregs, particularly nTregs, however this has not yet been 
conclusively established (Kim et al., 2012, Yadav et al., 2012). 
2.6.3 ROLES OF DENDRITIC CELLS AND INTERLEUKINS IN DEVELOPMENT 
AND FUNCTION 
The development and differentiation of iTregs is mediated by tissue-resident plasmacytoid 
dendritic cells (DCs) and cytokines present in the local microenvironment (Steinman et al., 
2003, Zou et al., 2010, Kushwah and Hu, 2011). Plasmacytoid DCs represent a distinctive 
DC population (Gehrie et al., 2011) that secrete IL-27, IL-10 and TGF-β, which induce 
Foxp3 in naïve T cells and drive their differentiation into iTregs (Kushwah and Hu, 2011) 
(Figure 2.2). Plasmacytoid DCs express indoleamine-2,3-dioxygenase (IDO), an enzyme 
which directly activates resting Tregs and maintains Treg suppressive activity (Chen et al., 
2009). Blockage of IDO causes conversion of Tregs to a pro-inflammatory phenotype 
resembling Th-17 cells (Brandacher et al., 2008, Chen et al., 2009). Plasmacytoid DCs can 
down-regulate the suppressive function of Tregs by certain signals such as CD137 which is a 
DC cell-surface molecule with co-stimulatory activity and cross-links with Tregs (Choi et al., 
2004, Kanamaru et al., 2004). 
 
Various ILs also enhance Treg development and release them from anergic state (Figure 2.2). 
Roles of important ILs in Treg development are summarised in Table 2.5.   
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Table 2.5. Roles of important interleukins (ILs) in regulatory T cell (Treg) development. 
Interleukin Roles in Treg development References 
IL-1 -Releases iTregs from anergic state 
- ↑ iTreg response to proliferation signals 
(Kubo et al., 2004, Brinster and Shevach, 2008) 
IL-2 -Converts CD25
- 
into CD25+ phenotype 
- ↑ nTreg proliferation 
-Releases nTregs from anergic state 
(Takahashi et al., 1998, Thornton and Shevach, 
1998, Yagi et al., 2004, Malek et al., 2008) 
IL-4 -↑ survival and proliferation  (Thornton et al., 2004, Pace et al., 2005) 
IL-6 -Releases iTreg cells from anergic state  
- ↑ iTreg response to other cytokines 
-Inhibits transforming growth factor-beta 
induced iTreg differentiation 
- ↓ Foxp3 expression  
(Kubo et al., 2004, King and Segal, 2005) 
IL-7  Survival factor for iTregs  (Harnaha et al., 2006, Li et al., 2011) 
IL-12 - ↑ anti-inflammatory IL-10 production  
- ↓ suppressive ability (but Foxp3 
expression not significantly altered) 
(Pasare and Medzhitov, 2003, King and Segal, 
2005) 
IL-15 Enhances iTreg survival and expansion and 
can replace IL-2 function  
(Koenen et al., 2003, Curotto and Lafaille, 2009) 
 
2.6.4 MECHANISMS OF IMMUNE SUPPRESSION  
Broadly, Tregs have four suppressive mechanisms but their function may be the result of one, 
two or a combination of all of these mechanisms (Vignali et al., 2008, Guerin et al., 2009). 
Suppression by inhibitory cytokines: Induced Tregs (Tr1 and Th3) suppress immune 
responses by secreting inhibitory cytokines such as IL-10 and TGF-β (Figure 2.3) 
(Dieckmann et al., 2001, Green et al., 2003, Annacker et al., 2003, Stassen et al., 2004, 
Fahlén et al., 2005, Loser et al., 2007, Bergmann et al., 2007, Erhardt et al., 2007, Collison et 
al., 2007). In contrast, nTregs exert their suppressive functions through cytokine independent 
and cell-to-cell contact-dependent mechanisms, although paracrine action through TGF-β and 
IL-10 may enhance contact-dependent manner of suppression (Annacker et al., 2003).  
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Figure 2.3. Treg have four mechanisms of action which include suppression by inhibitory cytokines, 
cytolysis, metabolic disruption and targeting dendritic cells. Adapted from (Workman et al., 2009). 
Suppression by cytolysis: Naturally occurring Tregs produce and release granzymes A and 
B and perforins to induce death in target cells (Grossman et al., 2004, Cao et al., 2007). In a 
mouse model, nTregs with deficient expression of granzymes have depressed suppressive 
action (Gondek et al., 2005) (Figure 2.3).  
Suppression by metabolic disruption: Induced Tregs act on helper T cells through 
mechanisms which cause ‘metabolic disruption’ (Vignali et al., 2008). For example, iTregs 
may use all available IL-2, which regulates the expansion of newly activated T lymphocytes 
and NKs and deplete other target cells of  IL-2 required for their development and survival, 
leading to cell death (de la Rosa et al., 2004, Sakaguchi, 2004). In addition, iTregs produce 
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anti-inflammatory adenosine that binds to its receptor on helper T cells and inhibits their 
function and enhances generation of iTregs by inhibiting IL-6 expression and promoting 
TGF-β secretion (Zarek et al., 2008) (Figure 2.3).  
Suppression by targeting dendritic cells: Interactions between CTLA-4, a protein receptor 
present on iTregs, and CD80 and 86 on DCs condition DCs to express IDO that suppresses 
helper T cells as described in section 2.6.2 (Figure 2.3).  
2.6.5 FUNCTIONS 
Tregs are potent suppressors of the immune system (Guerin et al., 2009) and perform their 
functions by suppressing proliferation and cytokine production of  immune cells (Sakaguchi 
et al., 2009). Natural and iTregs perform slightly different functions. While nTregs are 
concerned with establishment and maintenance of immune-tolerance against self-antigens to 
prevent auto-immune diseases, iTregs have mainly anti-inflammatory function against 
foreign antigens (Guerin et al., 2009, Corthay, 2009, Yadav et al., 2013). However, roles of 
nTregs against non-self-antigens cannot be completely ruled out (Ray et al., 2010). Induced 
Tregs, on the other hand, appear to have limited roles in establishing self-tolerance in the 
absence of nTregs. In a mouse model, removal of thymus on day three after birth results in 
organ-specific autoimmune diseases due to lack of nTreg development, which can be 
prevented by adoptive transfer of Tregs (Sakaguchi et al., 1995, Asano et al., 1996). Induced 
Tregs, by controlling the inflammatory responses, protect airways and the intestinal mucosae 
from non-self-antigens (invading microbes and environmental factors) and commensal 
bacteria from elimination by the immune system. Their local control of inflammation in 
tissues may be transient due to short lifespan of iTregs (Yadav et al., 2013). Induced Tregs 
also prevent inflammation of the testes and ovaries (orchitis and oophoritis, respectively) and 
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rejection of organs in recipients. Sperms and oocytes express a range of antigens and when 
administered to recipients can induce autoimmune inflammation (Guerin et al., 2009). 
 
Natural Tregs can induce suppressive properties or ‘infectious tolerance’ in other T cell 
populations, which is due to nTreg mediated conversion of suppressed T cells into iTregs 
(Curotto and Lafaille, 2009). Co-culture of nTregs with naïve CD4+ T cells causes iTreg 
formation with IL-10 or TGF-β-dependent suppressive activity (Qiao et al., 2007).  
 
2.6.6 ROLES IN DISEASES
Natural Tregs and iTregs must maintain a fine balance between suppressing potential 
autoimmune responses while controlling responses to foreign antigens at the same time 
(Workman et al., 2009). Achieving this balance can be contradictory as Treg sub-populations 
may over- or under-perform. Occasionally Tregs are unable to mediate peripheral tolerance 
leading to an exacerbated inflammatory/allergic reaction or autoimmunity. Similarly, 
imbalances can be detrimental by preventing effective anti-tumour responses and immunity 
against certain chronic infectious agents (Workman et al., 2009). 
In humans, reduced numbers and/or dysfunction of nTregs may result in auto-immune 
diseases such as rheumatoid arthritis, inﬂammatory bowel disease, multiple sclerosis, type I 
diabetes mellitus, systematic lupus erythematosus and X-linked syndromes such as IPEX and 
XLAAD (De Kleer et al., 2004, Viglietta et al., 2004). IPEX is characterised by dys-
regulation of immune system, endocrine glands and bowel and XLAAD by diarrhoea, 
dermatitis, insulin-dependent diabetes, thyroiditis and anemia (Li et al., 2007, Brusko et al., 
2008).  
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Induced Tregs may have roles in providing immunity in chronic viral infections (such as 
hepatitis C) (Robertson and Hasenkrug, 2006) in addition to allergies, asthma and parasitic 
and bacterial infections (such as H.pylori) (Robinson, 2009). However, Treg response during 
infections may be an important barrier for vaccination (Workman et al., 2009). Similarly, 
Tregs may obstruct tumor response to immune-therapies as tumor tissue promotes conversion 
of naive T cells into nTregs, which can then induce ‘infectious tolerance’ and local 
accumulation of Tregs, and impair the development of effector responses (Nishikawa et al., 
2003).  
 
2.6.7 EFFECT OF AGING ON Treg NUMBERS AND FUNCTION 
After puberty, the thymus progressively degenerates and its capacity to produce new T cells 
substantially declines (Lin et al., 2013). In adult life, thymic T cell production declines by  
3 % per year until reaching a very low level by 45 years of age (Berzins et al., 2002). 
However, the total number of T cells in the periphery remains unchanged due to peripheral 
mechanisms of T cell renewal (Steinmann and Muller-Hermelink, 1985, Berzins et al., 2002). 
The effect of aging on Treg numbers and function in humans have not been studied in detail 
but available evidence suggests only minor changes in the circulating total Treg pool (Dejaco 
et al., 2006, Raynor et al., 2012). Cord blood at birth contains the highest numbers of total 
Tregs, which decline until the third year of life and remain relatively stable thereafter 
(Sullivan et al., 2002). Tregs comprise 0.6-15 % of the total CD4+ cell pool in healthy adults 
(Dejaco et al., 2006). It is suggested that in adult life the total Treg pool is maintained by 
increased peripheral conversion of non-regulatory T cells into Tregs (Curotto de Lafaille et 
al., 2004).  
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Treg function in terms of anti-inflammatory cytokine production is significantly reduced in 
the aged (> 60 years) compared to the younger (< 40 years) population (Hwang et al., 2009). 
Decreased Treg function may contribute to increased risk of certain auto-immune diseases 
and malignancies in the elderly (Fessler et al., 2013). It is suggested that rather than the  total 
numbers of Tregs, Treg function and relative proportions of nTregs and iTregs in the total 
pool may be more important in preventing inflammatory changes and immune responses 
(Fessler et al., 2013, Schlossberger et al., 2013).  
 
2.7 REGULATORY T CELLS IN FEMALE REPRODUCTION  
The roles of other T cells in the normal menstrual cycle, endometriosis and unexplained 
infertility have been previously summarised in tables 1.2, 1.3 and 2.1, respectively. Tregs 
play important roles in many aspects of female reproduction (Robertson et al., 2009). These 
roles are reviewed below. It should be noted that, except in the case of normal pregnancy, 
roles of iTregs in female reproduction are currently less well known and it has been indicated 
in a mouse model that they may be less crucial than those of nTregs (Guerin et al., 2009, 
Guerin et al., 2011).  
2.7.1 IN THE OVARY 
Tregs are present in the ovaries and have roles in self-tolerance of ovarian antigens, corpus 
luteal function and premature ovarian failure (Facciabene A et al., 2012). There are several 
ovarian-related antigens (such as zona pellucida antigens) which are not expressed until 
sexual maturity. Induced Tregs ensure that normally there is no auto-reactivity against 
ovarian self-antigens (Robertson et al., 2009). Abundance of Tregs in the mid-cycle corpus 
luteum may support normal progesterone release (and pregnancy) by suppressing pro-
inflammatory cytokine synthesis (Robertson et al., 2009). Bovine studies have shown that 
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there is a sharp decline in Foxp3+ Treg numbers soon after the corpus luteum starts 
degenerating (Poole and Pate, 2012). In a mouse model, premature ovarian failure has been 
shown to be associated with disturbances in regulatory mechanisms in the ovary and its 
draining lymph nodes (Alard et al., 2001, Samy et al., 2006). In humans, altered Treg 
numbers and/or their dysfunction may adversely affect ovarian function and contribute to 
premature ovarian failure (Robertson et al., 2009, Facciabene A et al., 2012).  
2.7.2 THE MENSTRUAL CYCLE 
Although early studies failed to detect changes in the numbers of circulating Tregs during the 
various phases of the menstrual cycle (Prieto and Rosenstein, 2006), more recently it has 
been found that Tregs change in numbers in different phases of the menstrual cycle in the 
endometrium (Berbic et al., 2010) and peripheral blood (Arruvito et al., 2007).  
Endometrial density of Foxp3+Tregs increases linearly from early to the late proliferative 
phase but decreases significantly in the secretory phase (Berbic et al., 2010). The pre-
ovulatory surge of Tregs in the endometrium may reflect the importance of these cells in 
inducing immune-tolerance for successful implantation (Guerin et al., 2009). In a mouse 
model, natural and iTregs are increased in the endometrium and peripheral blood around the 
peri-implantation period (Aluvihare et al., 2004). Similarly, in fertile non-pregnant women, 
Tregs in circulation reach the maximum numbers during day 9-13 of the menstrual cycle (late 
proliferative phase) just before ovulation but there is a dramatic reduction in the numbers of 
Tregs during the secretory phase. Treg numbers and oestrogen concentration in peripheral 
blood positively correlate (Arruvito et al., 2007). 
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2.7.3 NORMAL PREGNANCY 
For survival and development of the embryo, it is essential that the peripheral tolerance 
mechanisms suppress maternal immune responses to paternal-origin fetal antigens (Aluvihare 
et al., 2004, Guerin et al., 2009, Hsu et al., 2012). Tregs play a part in preventing fetal 
rejection during pregnancy (Trowsdale and Betz, 2006) by various mechanisms which 
include suppression of pro-inflammatory Th1 cells and cytotoxic CD8+ cells and enhanced 
expression of anti-apoptotic molecule heme-oxygenase-1 (HO-1) (Mellor and Munn, 2001, 
Cosmi et al., 2004, Sollwedel et al., 2005, Brandacher et al., 2008, Chen et al., 2009).                                                           
EARLY PREGNANCY: Treg numbers increase in the endometrium or decidua very early 
in the normal pregnancy that is associated with increased expression of Foxp3 mRNA soon 
after implantation (Aluvihare et al., 2004, Somerset et al., 2004, Thuere et al., 2007, Hsu et 
al., 2012). The uterine draining lymph nodes appear to be the main site of iTreg proliferation 
in early pregnancy (Zhao et al., 2007). Although the mechanisms are not well understood, the 
decidual antigen-presenting cells help iTregs over-express in the decidua during early 
pregnancy in relation to nTregs (Hsu et al., 2012). In contrast to nTreg, which raise the 
threshold for all immune responses, iTregs may specifically maintain a non-inflammatory 
environment in the uterus in early pregnancy to suppress immune responses to the fetal 
antigens (Curotto and Lafaille, 2009). Increased oestrogen levels during pregnancy may be 
the underlying drive for expansion of Treg numbers (Polanczyk et al., 2004). Other 
pregnancy hormones, such as human chorionic gonadotropin, also have the capacity to attract 
Tregs to the feto-maternal interface and enhance their Foxp3 expression and suppressive 
activity (Schumacher et al., 2009).  
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MID PREGNANCY: During normal pregnancy, there is continued expansion of the 
peripheral and decidual Treg populations over the first two trimesters. Treg numbers peak in 
the second trimester and are higher in the decidual tissue than in the peripheral blood (Sasaki 
et al., 2004, Somerset et al., 2004, Guerin et al., 2009).  
LATE PREGNANCY: Initially it was indicated that endometrial Treg numbers start  
decreasing from mid-pregnancy and reach non-pregnant levels just before delivery at term 
(Zhao et al., 2007). Lower levels of Tregs at term were thought to have a role in the initiation 
of labour and fetal expulsion (Guerin et al., 2009). More recent research reports that Treg 
numbers are not changed before or during labour, but their suppressive activity is decreased 
in labouring women compared with non-labouring women at term (Schober et al., 2012, 
Gomez-Lopez and Laresgoiti-Servitje, 2012). At present, changes in Treg function at term 
and possible mechanisms in initiation of spontaneous term labour are not well understood 
(Schober et al., 2012). 
 
2.7.4 PREGNANCY RELATED COMPLICATIONS 
Tregs have been implicated in pathological processes in a range of pregnancy-related 
complications, including unexplained infertility, recurrent miscarriage, pre-eclampsia and 
pre-term birth. The known roles of Tregs in these pregnancy-related complications are 
reviewed below. Possible roles of Tregs in endometriosis-associated infertility will be 
discussed separately in section 2.7.6. 
INFERTILITY: As discussed in section 2.2.1, infertility is associated with a range of 
cellular and molecular defects in the endometrium (Lee et al., 2011). Disturbances in the 
numbers/function of Tregs may be associated with unexplained infertility or sub-clinical 
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pregnancy loss (Guerin et al., 2009). In women with unexplained infertility, endometrial Treg 
Foxp3 mRNA expression is significantly reduced in the mid-secretory phase compared to 
fertile controls (Jasper et al., 2006). It is suggested that unexplained infertility may result 
from impaired endometrial recruitment of Tregs or differentiation of uterine T cells into 
iTregs (iTregs) (Jasper et al., 2006, André et al., 2011). In a mouse model, adequate Treg 
function is necessary to suppress Th1-mediated pro-inflammatory maternal immune 
responses to the embryo (Aluvihare et al., 2004). Treg dysfunction may, therefore, cause fetal 
rejection and unexplained infertility (Guerin et al., 2009).  
Relative proportions of circulating Treg sub-populations are altered in infertile women with 
successful ART outcome compared to those who failed to conceive after such treatment 
despite no differences in the total Treg numbers (Schlossberger et al., 2013). It is 
hypothesised that Treg sub-populations may have more influence on establishing pregnancy 
rather than their absolute numbers (Schlossberger et al., 2013). 
MISCARRIAGE: Recurrent miscarriage is the loss of at least three consecutive pregnancies 
before 20 weeks (Ford and Schust, 2009). In women with recurrent miscarriage, Treg 
numbers are markedly reduced in the endometrium and peripheral blood compared to normal 
pregnancies or isolated cases of spontaneous abortion (Sasaki et al., 2004, Arruvito et al., 
2007, Yang et al., 2008, Cao et al., 2014). Furthermore, in women with a history of recurrent 
miscarriage, the expected increase in endometrial Treg numbers in the late proliferative phase 
is not observed (Arruvito et al., 2007). Tregs may also be functionally less effective in these 
women due to an intrinsic defect (Arruvito et al., 2007). If Tregs are depleted in numbers or 
function, insufficient suppression of pro-inflammatory Th1 mediates fetal loss (Aluvihare et 
al., 2004). As such, Treg depletion after implantation in a mouse model causes early 
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pregnancy failure (Zenclussen, 2005). However, if Tregs are transferred from normal 
pregnant mice to abortion-prone mice, the increased risk of abortion is reversed (Zenclussen, 
2005).  
PRE-ECLAMPSIA: Pre-eclampsia is characterised by the development of new onset raised 
blood pressure (hypertension) in association with significant protein loss in urine after 20 
weeks of gestation (Chanprapaph, 2004, Sibai, 2006). It is part of an abnormally increased 
maternal inflammatory response to pregnancy where pro-inflammatory Th1 responses 
dominate and there is exaggerated immune reaction against the fetus (Can et al., 2011). This 
may be secondary to insufficient Treg numbers and/or function (Saito and Sakai, 2003, 
Sargent et al., 2006, Guerin et al., 2009). Recent studies favour a significant decrease in the 
numbers of Tregs in the decidua and peripheral blood of women with pre-eclampsia 
(Paeschke et al., 2005, Darmochwal-Kolarz et al., 2007, Quinn et al., 2011, Quinn and Parast, 
2013, Zeng et al., 2013). It is thought that in pre-eclampsia, diminished numbers and/or 
function of Tregs cause decreased IDO levels in the placenta or insufficient suppression of 
the pro-inflammatory Th17 cells. Decreased IDO levels alter Treg function by converting 
them to a phenotype resembling the pro-inflammatory Th-17 cells (Santoso et al., 2002, 
Grohmann and Puccett, 2002, Nishizawa et al., 2007, Brandacher et al., 2008, Liu et al., 
2011) as discussed in section 2.6.3.  
PRETERM LABOR: Preterm delivery is associated with significantly reduced placental 
Treg density and decidual Treg suppressive activity compared to uncomplicated term 
pregnancies (Steinborn et al., 2012, Schober et al., 2012, Quinn and Parast, 2013). In preterm 
labour, a pro-inflammatory micro-environment in the absence of adequate Treg numbers 
and/or function may facilitate the initiation of labour. However, the exact mechanisms 
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underlying preterm labor are not understood (Gomez-Lopez and Laresgoiti-Servitje, 2012, 
Quinn and Parast, 2013).    
2.7.5 ENDOMETRIOSIS 
Tregs are dysregulated in women with endometriosis (Berbic et al., 2010). As described 
earlier in section 2.7.2, in the normal menstrual cycle, endometrial Treg numbers decrease 
during the secretory phase (Arruvito et al., 2007). In the eutopic endometrium of women with 
endometriosis, the numbers of Foxp3+ Tregs are significantly increased in the secretory 
phase of the menstrual cycle compared to women without the disease (Berbic et al., 2010) 
(Figure 2.4).  
 
 
Figure 2.4. Comparison of endometrial Treg numbers in women with and without endometriosis. * Treg 
numbers are significantly increased in the secretory phase compared to controls  (Berbic et al., 2010). 
 
It is suggested that increased presence of Tregs in the secretory phase in endometriosis may 
suppress the recruited endometrial leucocytes and hence allow survival of the shed 
endometrial fragments, facilitating their implantation in the peritoneal cavity (Berbic et al., 
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2010). The exact mechanism of Treg immuno-suppression of other cells in this scenario is 
not well understood but may include interference with phagocytic function of macrophages 
and maturation of dendritic cells (Berbic et al., 2010). Local oestrogen production in the 
endometrium of women with endometriosis may provide positive feedback for increased 
Treg proliferation (Zeitoun et al., 1998, Berbic et al., 2010). 
 
Tregs appear to mobilise from blood to the peritoneal cavity in the early proliferative phase in 
women with endometriosis as circulating Treg numbers are markedly decreased in blood 
compared to the peritoneal lesions (Olkowska-Truchanowicz et al., 2013). In women with 
endometriomas, the density of Tregs is increased in the peritoneal fluid compared to women 
without the disease (Olkowska-Truchanowicz et al., 2013). Foxp3+ Tregs are also present in 
some peritoneal endometriotic lesions and in lesions in a baboon model of endometriosis 
(Berbic et al., 2010, Braundmeier et al., 2012). It is thought that presence of Tregs in the 
lesions may be dependent on the progression and stage of endometriotic lesions. Active 
trafficking of Treg cells to the endometrium, peritoneal lesions and/or peritoneal fluid may be 
a compensatory anti-inflammatory mechanism in women with endometriosis, a known 
inflammatory condition (Olkowska-Truchanowicz et al., 2013).
In addition to changes in the Treg populations in the uterus, circulation and the peritoneal 
cavity, certain genetic polymorphisms of Foxp3 mRNA in the endometrium are positively 
and significantly correlated with the presence of endometriosis (André et al., 2011). Foxp3 
gene polymorphisms can cause altered numbers or function of Tregs, which can contribute to 
the pathogenesis of endometriosis (Barbosa et al., 2012). It is hypothesised that in 
endometriosis, Tregs over-suppress immune cell responses and allow the menstrual 
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fragments to implant at ectopic sites (Berbic et al., 2010), however, the exact mechanisms of 
Treg action in endometriosis are yet unknown. 
 
2.7.6 POSSIBLE ROLES OF Tregs IN ENDOMETRIOSIS-ASSOCIATED 
INFERTILITY 
The possible roles of Tregs in endometriosis-associated infertility are currently unknown and 
may be different to those in other types of infertility. However, given the implications of 
Tregs in both infertility (Jasper et al., 2006, André et al., 2011) and endometriosis 
pathophysiology (Berbic et al., 2010, Olkowska-Truchanowicz et al., 2013), important roles 
of Tregs in endometriosis-associated infertility are indicated. The fertility status of women 
was not reported or unknown in studies that suggested roles of endometrial or circulating 
Tregs in endometriosis (Berbic et al., 2010, Olkowska-Truchanowicz et al., 2013). Similarly, 
presence or absence of endometriosis was laparoscopically confirmed in only one (André et 
al., 2011) of the two studies that suggested reduced endometrial expression of Foxp3 in 
unexplained infertility (Jasper et al., 2006). Therefore, it is now of considerable interest to 
better understand roles of Tregs in the pathophysiology of infertility in endometriosis. 
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CHAPTER 3: HYPOTHESES, AIMS AND OBJECTIVES 
 
3.1 INTRODUCTION
Endometriosis is an enigmatic disease with a number of postulated theories of pathogenesis. 
It is widely thought that during menstruation, shed endometrial fragments reach the 
peritoneal cavity via retrograde flow and can implant to form endometriotic lesions. Evidence 
suggests that endometriosis is an endometrial disease where the eutopic endometrium is 
altered compared to the endometrium of women without the disease in a number of ways, 
which may facilitate establishment of endometriotic lesions. This indicates that the primary 
defect in endometriosis may be in the uterine endometrium. Importantly, immunological 
responses, which recognise and target the shed endometrial cells, are disturbed in 
endometriosis. Endometriosis is a leading cause of infertility but the exact aetiology of this 
infertility remains unknown. It has been shown that specific immunological mechanisms play 
crucial roles in the establishment and maintenance of pregnancy. Immunological alterations 
may contribute to the pathogenesis of endometriosis-associated infertility.   
Regulatory T cells control and suppress a range of immune responses at local and systemic 
levels. In the endometrium of women with endometriosis, Treg numbers are high in the 
secretory phase of the menstrual cycle. In the endometrium of women without endometriosis, 
their numbers greatly decrease. It is suggested that in endometriosis, increased presence of 
endometrial Tregs may suppress the ability of other immune cells in the endometrium to 
effectively target shed menstrual fragments, although this is not well understood. Preliminary 
indications are that numbers and/or function of Tregs may be inadequate in infertility. 
However, it is currently unknown whether Tregs are altered in endometriosis-associated 
infertility.
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3.2 HYPOTHESES 
3.2.1 PRIMARY HYPOTHESIS 
The primary hypothesis of this work is that the numbers of Tregs are altered across the 
menstrual cycle in circulation and the endometrium between fertile and infertile women with 
and without endometriosis. 
 
3.2.2 SECONDARY HYPOTHESES 
The secondary hypotheses of this project are as follows:  
 Circulating and endometrial Treg numbers are increased in the secretory phase in 
women with endometriosis compared to women without the disease.
 The numbers of Tregs are increased in circulation and the endometrium of fertile 
women compared to infertile women.
 Tregs are decreased in numbers in circulation and the endometrium of infertile 
women with endometriosis compared to fertile women with and without 
endometriosis.  
 
3.3 AIMS
To test the hypotheses stated above, this project aimed: 
 To examine Tregs in circulation and the endometrium during the menstrual cycle in 
women with endometriosis and associated infertility compared women without 
endometriosis (both fertile and infertile). 
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3.4 OBJECTIVES 
The main objective of this study was to investigate the roles that Tregs may play in the 
pathogenesis of endometriosis and particularly in the mechanisms of endometriosis-
associated infertility. Specifically, the objectives included:
 Study of circulating and endometrial Tregs in fertile and infertile women with and 
without endometriosis during the menstrual cycle. 
 Determination of Tregs change during the menstrual cycle in circulation and the 
endometrium of fertile and infertile women with and without endometriosis. 
 Determination of differences in Tregs in circulation and the endometrium between 
fertile and infertile women with and without endometriosis. 
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CHAPTER 4: METHODOLOGY 
 
Treg analyses were performed by two methods: flow cytometry and immunohistochemistry. 
4.1 ETHICS APPROVALS 
Ethics approvals for the study were granted by the Human Ethics Committees of Sydney 
Local Health District (Royal Prince Alfred Hospital RPAH zone; Protocol No X12-0344, 
HREC/12/RPAH/525 & SSSA/13/RPAH/36) and The University of Sydney (Project No 
2013/112).  
 
4.2 SAMPLE SIZE CALCULATION 
Sample size was calculated to determine statistical power of the study. Sample size 
calculation was performed by using WHO sample size calculator with the fixed level of 
significance at 5% (to exclude type I statistical errors) and fixed power of the test at 90% (to 
rule out type II errors). The statistically calculated required sample size was 108 (54 in each 
group).  
 
4.3 FLOW CYTOMETRY 
Blood and endometrial Treg populations were studied with multi-colour flow cytometry. 
 
4.3.1 PATIENT RECRUITMENT 
Patients were recruited for one full year. Infertile and fertile women of reproductive age (18-
45 yrs) with an intact uterus and with or without laparoscopically-confirmed endometriosis 
(peritoneal, ovarian and/or DIE lesions observed and histologically confirmed) were included 
in the study (n = 50). For the purpose of this experiment, infertility was defined as inability to 
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conceive for at least one year while having regular sexual intercourse and not using any 
method of contraception (Hamada et al., 2012). Women on hormonal or immuno-suppressive 
therapy, with a history of autoimmune disease or recent infection (within the past two weeks) 
were excluded. Due to strict inclusion criteria and difficulty in finding controls, the ideal 
sample size according to power calculations could not be achieved.  
 
All participants gave written, informed consent. Detailed clinical history was taken at the 
time of recruitment in a standard format. Age, date of last menstrual period, fertility history 
and parity, symptoms such as dysmenorrhea, pelvic pain and abdominal bloating, previous 
gynaecological diagnoses and surgeries, and current medications were noted. Menstrual cycle 
phase was determined by dating of the histological appearance of the endometrium by an 
experienced gynaecological histopathologist (Noyes et al., 1950).
 
4.3.2 COLLECTION OF SAMPLES 
4.3.2.1 BLOOD  
Blood samples were collected from infertile and fertile women with (n = 37) and without (n = 
13) endometriosis by routine phlebotomy, immediately before or after receiving general 
anaesthesia for diagnostic/operative laparoscopy. One sample was collected from each 
patient. Blood was collected into cell preparation tubes (Vacutainer CPT, BD Biosciences, 
USA). The vacutainer cell preparation tube is an 8 mL draw capacity blood collection tube 
with anticoagulant (sodium citrate) and a density gradient fluid layer (polysaccharide/sodium 
diatrizoate). A polyester gel barrier acts as a blood separation medium and with 
centrifugation; low density white blood cells and plasma are separated from the denser blood 
components. At least 7 mL blood was collected from each participant. Tubes were gently 
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inverted to mix the contents then kept upright at room temperature. Samples were processed 
within 1 hour of blood collection.  
 
4.3.2.2 ENDOMETRIUM
A hysteroscopically-directed endometrial sample was taken from infertile and fertile women 
with (n = 20) and without (n = 13) endometriosis, immediately before or after laparoscopy, 
and collected into gentleMACS dissociator C tube (Miltenyi Biotec, Germany) containing 5 
mL of buffer (See appendix A). The tubes were weighed before and after tissue collection. 
Time of collection and processing of samples were noted and all samples processed within 
one hour of collection.  
 
4.3.3 PROCESSING OF BLOOD AND ENDOMETIAL SAMPLES 
4.3.3.1 BLOOD PROCESSING 
Blood was mixed by gently inverting the tube before centrifugation at 1600 relative 
centrifugal force (RCF), 21 °C and the brake off (Deceleration 0) for 15 minutes. 
Centrifugation separated the cells of interest (white blood cells) from red blood cells and 
platelets. After centrifugation, white blood cells accumulated in the buffy coat layer, which 
separated the platelet-rich serum (above) from the packed red cells (below) (Figure 
4.1). Supernatant (serum) was aspirated and discarded and the white cell layer collected in a 
15 mL falcon tube. Cells were washed twice, tube was filled to the top with phosphate 
buffered saline (PBS) (See appendix B) and centrifuged at 300 RCF, 5 °C, 7 minutes, 
deceleration 9 (DEC 9), supernatant was discarded and cells resuspended in PBS.  
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Figure 4.1. Components of a blood sample in a BD Vacutainer Cell Preparation Tube after 
centrifugation.   
 
4.3.3.2 DISSOCIATION OF TISSUE  
Tissue samples were dissociated using gentleMACS, a bench top instrument for automated 
tissue dissociation to obtain single-cell suspensions with a high viability rate (Miltenyi 
Biotec, Germany). It ensures safety and reproducibility. The plastic rotor uniformly 
dissociates samples in the C tube by spinning in clock- and counter-clock directions to 
generate single-cell suspensions. It is equipped with 23 specific and 5 (A-E) general 
programmes. Programme A is suitable for dissociation of soft tissues, whereas, programme E 
is used for harder tissues. In this experiment, the endometrial tissue was processed with 
gentleMACS using pre-set general programme C followed by B (31 seconds, setting B_ 01).   
 
After gentleMACS, tissue was further dissociated using 5 % type IV collagenase (0.0043 g 
Worthington, USA), which was added to the sample in the tube. The sample was incubated 
on a rocker for 20 minutes at 37 °C. The sample was then filtered through a 70 µm Filcon 
filter (BD Biosciences, USA) into a 15 mL falcon tube to remove large fragments. The tube 
was filled to the top with buffer. After centrifugation (300 RCF, 5 °C, 7 minutes, DEC 9), 
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cells were resuspended in 4 mL pre-diluted 1 in 10 red blood cell lysis (RCL) solution 
(Miltenyi Biotec, Germany). RCL solution lyses erythrocytes but has minimal effects on 
leukocytes. Lysing samples were incubated in the dark for 10 minutes at room temperature. 
After 10 minutes, samples were centrifuged (300 RCF, 5 °C, 7 minutes, DEC 9), supernatant 
was discarded and cells were washed with PBS.  
 
After these initial steps, blood and tissue samples were processed in a similar fashion. 
Samples were transferred to a 5 mL falcon tube as clean, single cell suspensions that were 
stained as described in the following section.   
 
4.3.4 CELL STAINING 
4.3.4.1 LIVE/DEAD CELL STAINING  
Endometrial cells and peripheral blood leukocytes were initially labelled with a fluorescent 
dye to differentiate between live and dead cell populations. Live/dead fixable dead cell stain 
(near-infrared [Near-IR] fluorescent reactive dye; Life Technologies, Australia) consists of a 
reactive dye, which easily penetrates necrotic/dead cell membranes. Dead cells generate a 
strong signal while viable/live cells produce a relatively dim signal. Near-IR dye requires 
excitation at approximately 633-635 nm and emits light at 665 nm.
 
The Live/Dead Fixable Dead Cell Stain Kit was stored at -20 °C, away from light. Prior to 
use fluorescent reactive dye (Component A) and anhydrous dimethylsulfoxide (DMSO) 
(Component B) vials were brought to room temperature and 50 µL of Component B was 
added to a vial containing a pre-determined mass of Component A. Blood and tissue single 
cell suspensions in 5 mL falcon tubes were re-suspended in 1 mL PBS and 1 µL live/dead 
marker was added. The tubes were protected from light, incubated at room temperature for 15 
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minutes and centrifuged (300 RCF, 5 °C, 7 minutes, DEC 9). Supernatant was discarded and 
cells were washed before staining with Treg antibodies (described in section 4.3.4.2). 
 
4.3.4.2 REGULATORY T CELL STAINING
Antibodies are glycoproteins and part of a group of proteins called immunoglobulins (Ig). 
They are formed by B lymphocytes in response to exposure to a foreign antigen. An antibody 
is typically Y-shaped and made up of two identical heavy chains (H) and two identical light 
chains (L) joined by covalent inter-chain disulfide bonds (Boenisch, 2001) (Figure 4.2). 
The fragment antigen-binding (Fab fragment) region at the tip of the Y-shaped antibody 
binds to antigens. It is composed of one constant and one variable domain of each of 
the heavy and the light chain (Boenisch, 2001) (Figure 4.2). 
 
 
Figure 4.2. Fab (tip) and Fc (tail) fragments of Y-shaped antibody consist of variable and constant 
domains of heavy and light chains (Boenisch, 2001). 
Each antibody reacts with a specific site on a particular antigen called the ‘epitope’. An 
antigen may contain several epitopes. Therefore, one antigen may produce a variety of 
antibodies (Woychik et al., 1984). Antibodies can be polyclonal or monoclonal. Polyclonal 
antibodies are produced by different cells and are immunochemically dissimilar (Nakazawa 
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et al., 2010). Monoclonal antibodies are produced by an individual clone of plasma, are 
immunochemically identical and react with one specific epitope on the antigen against which 
they are raised. Polyclonal antibodies are produced in a range of animals, most commonly 
rabbits, while monoclonal antibodies are almost exclusively produced in mice (Nakazawa et 
al., 2010). 
Treg detection kit (Miltenyi Biotec, Germany) is an optimised antibody cocktail used for 
staining Tregs. It consists of antibodies for CD45 (clone: 5B1, isotype: mouse IgG2a), CD4 
(clone: VIT4, isotype mouse: IgG2a), CD25 (clone: 4E3, isotype: mouse: IgG2b) and CD127 
(clone: MB15-18C9, isotype: mouse IgG2a) conjugated to fluorochromes as detailed in Table 
4.1.  
 
Table 4.1. Fluorochromes used in this experiment. 
Marker Expressed by Expression by 
Tregs 
Antibody-conjugated 
fluorescent dye 
CD45 All leucocytes High Vio blue  
CD4 CD4 subgroup of lymphocytes High Fluorescein isothiocynate  
CD25 Activated Tregs, natural killer dendritic 
cells and B cells 
High Allophycocyanin  
CD127 Tregs, natural killer and most of CD8+ 
cells 
Low R- phycoerythrin  
 
Treg staining was performed by resuspending cells in 100 µL PBS, mixing in 10 µL antibody 
cocktail and incubating in the dark at 4 ºC for 10 minutes as per the manufacturers’ 
recommendations. After the staining incubation, samples were washed in 1-2 mL PBS and 
centrifuged (300 RCF, 5 °C, 7 minutes, DEC 9) and supernatant was discarded. 
  
4.3.4.3 FIXATION  
Fixation is necessary for biosafety reasons and to preserve light scattering characteristics and 
fluorescence intensities of stained cells for later flowcytometric analysis (Law et al., 2009). 
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Stained cells were fixed by re-suspension in 250 µL Cytofix
 
fixation buffer (BD Biosciences, 
USA), vortexed for 30 seconds and incubated for 15 minutes at 4 ºC. Cytofix
 
contains neutral 
pH-buffered saline (Dulbecco’s PBS) with 4 % weight per volume paraformaldehyde. After 
fixation, cells were washed (300 RCF, 5 °C, 7 minutes, DEC 9). Finally, the supernatant was 
discarded, cells resuspended in 200 µL of PBS and refrigerated for analysis by flow 
cytometry. 
 
4.3.5 FLOW CYTOMETER 
Flow cytometry is a powerful technique for rapid analysis of multiple quantitative and 
qualitative parameters of individual cells within heterogeneous populations. Flow cytometry 
measures optical and fluorescence characteristics of single cells and particles. It is used in a 
range of applications like immuno-phenotyping to study the proteins expressed by cells, 
ploidy analysis to predict the behaviour of DNA content in individual cells within a mixed 
population of cells and cell counting. Flow cytometry can be used to immuno-phenotype 
whole blood, solid tissues and other biological samples such as urine (Ibrahim and Van, 
2007). 
 
The flow cytometer performs analysis by passing thousands of cells per second through a 
laser beam and capturing the light that emerges from each cell as it passes through (Rowley, 
2013). This light signal can be transformed into data by software to report cellular 
characteristics (Ibrahim and Van, 2007). The primary components of a flow cytometer are the 
fluidics system (which presents samples to the ‘interrogation point’ and takes away waste), 
lasers (the light source), optics (direct the light), detectors (receive the light) and electronics 
and a peripheral computer system which convert signals from the detectors into digital data 
and perform the necessary analyses (Hedley and Keeney, 2013) (Figure 4.3). For the purpose 
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of these experiments, a BD FACSCanto II (BD Biosciences, USA) flow cytometer was used 
to perform multi-colour flow cytometry. 
 
Figure 4.3. Primary components of a flow cytometer, including fluidics, optics, lasers and electronics 
(Rowley, 2013). 
4.3.5.1 FLUIDICS 
There are two sources of fluid in a flow cytometer: a sheath fluid (usually PBS) and the 
specimen to be analysed. For accurate analysis, it is important that particles and cells are 
passed through the laser beam one at a time. In most flow cytometers, this is accomplished by 
injecting the sample stream containing the cells into the middle of the sheath fluid which then 
passes through the flow chamber and the ‘interrogation point’ where the laser and sample 
intersect and the optics collect the resulting signals. The outer sheath fluid ensures that the 
sample stream is compressed into single cell diameter which is called ‘hydro-dynamic 
focussing’ (Ibrahim and Van, 2007) (Figure 4.4). The FACSCanto II flow rate can be 
adjusted between low (10 μL/min) to medium (50 μL/min) to high (120 μL/min). In this 
experiment, samples were run at high flow rate (120 µL/min). After the sample is passed 
through the flow cytometer, it exits as waste.        
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Figure 4.4. Hydro-dynamic focussing is the process of compressing sample stream into single cell 
diameter. 
 
4.2.5.2 LASERS
Lasers are the principle light sources in flow cytometers, providing coherent light at high 
power in a form that can be easily directed and focused on a sample stream. Most modern 
flow cytometers have argon- and krypton-ion laser. They emit several monochromatic 
wavelengths simultaneously, produce high-quality beams with low noise and relatively long 
lifetimes before requiring gas tube replacement (Telford, 2011). The BD FACSCanto II has 
three lasers (488 nm solid state, 633 nm He Ne and 405 nm solid state) which can detect up to 
eight colours/fluorescence signals. 
When laser light strikes a cell, light is diffracted around the edges of the cell in the forward 
direction which is called forward scatter (FSC) or forward angle light scatter (FALS) (Figure 
4.5). The magnitude of forward scatter is roughly proportional to the size of the cell and has 
the same wavelength as the exciting laser light. (Rowley, 2013). A cell travelling through the 
laser beam scatters light at all angles. Side scatter is light scattered at 90 degrees from the 
laser path due to the granularity and structural complexity inside the cell. More granular cells 
have higher side scatter due to internal complexity (Figure 4.5). Samples consist of a large 
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number of cells and particles. To prevent data collection from particles which have little 
significance, such as debris and platelets, a threshold is set such that a certain forward scatter 
pulse size must be exceeded for the instrument to collect the data. 
 
 
Figure 4.5. Laser light is diffracted in all directions after striking a cell. Diffraction around the edges of 
the cell in the forward direction depends on the cell size and is called forward scatter (FSC) or forward 
angle light scatter (FALS). More granular cells have higher side scatter (Schneider and Grosschedl) due 
to internal complexity (Rowley, 2013). 
Forward and side scatter plots together identify small sized lymphocytes with low internal 
complexity, medium sized monocytes with slightly more internal complexity and larger 
neutrophils and other granular leukocytes with high internal complexity (Figure 4.6).  
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Figure 4.6. Forward versus side scatter plot identify leukocyte populations by cell size and internal 
complexity. Lymphocytes are identified by smaller size and low internal complexity compared to other 
leukocytes. 
4.3.5.3 FLUORESCENCE
Fluorescent probes, such as antibodies to cellular antigens with covalently-bound fluorescent 
dyes (fluorochromes), can be used to detect specific cell molecules. When antibody-labelled 
cells come across a light source, the ﬂuorescent compound absorbs light energy over a certain 
range of wavelengths which increase the energy level of its electrons for a short period of 
time. The excited electrons quickly return to their ground state and emit the excess energy as 
photons of light. This emission of light energy is called ‘ﬂuorescence’ (Figure 4.7). 
Fluorochromes with different excitation and emission wavelengths or colours allow analysis 
of multiple cellular characteristics simultaneously. Table 4.2 summarises the peak excitation 
and emission wavelengths of fluorescence dyes used in this experiment. 
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.  
Figure 4.7. Light source excites the antibody-labelled cell electrons to a higher energy level. Excess energy 
of electrons is emitted as photons on return to their ground state.  
 
Table 4.2. Peak excitation and emission wavelengths of fluorescent dyes used in this experiment.  
Fluorescent dyes used in 
this experiment 
 
Peak excitation 
wavelength (nm) 
Peak emission 
wavelength (nm) 
BD FACSCanto II 
excitation laser (nm) 
Colour 
emitted 
Vio blue  
 
400 452 405 Blue 
Fluorescein 
isothiocynate  
 
495 520 488 Green 
Allophycocyanin  
 
652 660 635 Red 
R- phycoerythrin  
 
565 578 488  Yellow 
 
4.3.5.4 OPTICS AND DETECTORS 
The optics system in the BD FACSCanto II cytometer is composed of both excitation and 
collection optics. The excitation optics consist of lasers, fibre optic cables, beam-shaping 
prisms and an achromatic focusing lens which bring light to the flow cell. From the flow cell, 
laser light is routed to the collection optics, which efficiently gather the signals emitted from 
each particle.  
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Light from the collection optics is directed to the appropriate detector which isolates different 
bands of wavelengths. There are two types of signal detectors in the BD FACSCanto II flow 
cytometer: the photomultiplier tube (PMT) and the photodiode. The more sensitive PMTs are 
used to detect the weaker signals generated by SSC and all fluorescence channels. Filters are 
used to capture peak fluorescence from a fluorochrome and direct it to a specific PMT. The 
photodiode is used to detect the stronger FSC signals (Lawrence et al., 2008).  
Once the light signals or photons strike one side of the PMT or the photodiode, they generate 
an electrical current by conversion into a proportional number of electrons that are multiplied. 
The electrical current travels to the amplifier and is converted to a voltage pulse. The highest 
point of the pulse occurs when the particle is in the centre of the beam. As the particle leaves 
the beam, the pulse comes back down to the baseline. The voltage pulse is assigned a digital 
value by an analog-to-digital converter. Data is then transferred to the computer and light 
signals are then displayed on a data plot. 
 
4.3.5.5 NOISE, SPECTRAL OVERLAP AND COMPENSATION 
Noise is an unwanted low-level background signal that occurs within the electronics of a flow 
cytometer. Noise can appear as collected events even when there are no actual cells or 
particles in the sample. In this experiment, threshold was set periodically depending on the 
fluorescent properties of cells. Fluorescent signal from each immune cell differentiated 
between particles of interest and unwanted debris.   
Spectral overlap occurs when portions of fluorochrome emission spectra overlap each other 
(Figure 4.8). This often occurs when multiple fluorescent-conjugated antibodies are used in 
the same sample. With spectral overlap, the observed signal in a detector is composed of the 
73 
 
 
 
true signal from the fluorochrome of interest and any overlapping signal from other 
fluorochromes.  
 
Figure 4.8. Spectral properties of two imaginary fluorochromes ‘A’ and ‘B’ are measured in channels FL-
1 and FL-2 of the flow cytometer, respectively. Dark blue and dark red shades represent the proportion 
of spectral overlap by fluorochrome ‘B’ and ‘A’, respectively. 
The amount of spectral overlap can be determined by running single colour controls and a 
mathematical algorithm applied to data to correct for spectral overlap (called 
‘compensation’). Compensation particles (BD CompBead anti-mouse Ig, κ; BD Biosciences, 
USA) were used at regular intervals to calculate the amount of spectral overlap and apply 
compensation in this project. Beads are ideal for compensation in experiments with rare cell 
types like Tregs (BD Biosciences, 2009). BD CompBead particles are polystyrene micro-
particles coupled to an antibody specific for the kappa light chain of immunoglobulin from 
mouse. When mixed together with each fluorochrome-conjugated mouse antibody, 
CompBeads provide distinct positive and negative (background fluorescence) stained 
populations which can be used to set compensation levels automatically using instrument set-
up software. In this experiment, automated compensation was setup by using BD FACSDiva 
software (BD Biosciences, USA). BD FACSDiva software collects data from each 
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compensation control tube and automatically calculates accurate compensation values for 
each fluorochrome combination. All of the spectral overlaps were stored as a flow cytometry 
standard (FCS) file for immediate use or later recall.  
4.3.5.6 DATA ACQUISITION AND ANALYSIS  
For these experiments, samples were run on the BD FACSCanto II until clear profile of cells 
was achieved or until the sample was exhausted. FlowJo software (TreeStar, USA) was used 
to view and analyse flow cytometric data. Each recorded flow cytometry event is visualised 
as a dot on a dotplot. Two parameters can be displayed simultaneously in a density plot with 
one parameter displayed on the x-axis and the other on the y-axis. FlowJo allows gating and 
statistical analyses in table and graphical forms. Gating is the process of selecting subsets of 
collected events (based on specific parameters) for further analysis. Subsets can be gated to 
generate further subsets, until a collection has only the cells for which a graphical display or 
statistics are desired. In order to phenotype cell populations, it is important to create a clear 
gating strategy. In flow cytometry, this is referred to as ‘gating hierarchy’. 
For Treg analyses, initially a gate was applied to select CD45+ leukocytes from other cell 
populations and debris (Figure 4.9 A). The next gate was applied to leukocyte events to 
discriminate lymphocytes from granulocytes and monocytes based on cell size (FSC-A) and 
internal granularity (SSC-A; Figure 4.9.B). The third gate was applied to these events, which 
comprised of lymphocytes only, to identify the proportion of live lymphocytes (Figure 4.9 C). 
The fourth gate was applied to the live lymphocyte events to detect CD4+ helper T cells 
(Figure 4.9 D). Finally, a gate was applied to the CD4+ helper T cell population to identify 
CD25+CD127
dim 
Treg cells (Figure 4.9 E). The final gate determined CD4+CD25+CD127
dim 
Treg numbers as a percentage of total CD4+ cells (Figure 4.9 E).  
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Figure 4.9. Gating strategy for identification of Tregs. A) Leukocyte population was gated from all 
recorded events. B) Lymphocytes were separated from other leukocyte sub-groups. C) Live lymphocytes 
were separated from all lymphocytes. D) Live CD4+ percentage of live lymphocytes was gated. E) The 
final gate shows CD4+CD25+CD127
dim 
Treg numbers as a percentage of total CD4+ cells. 
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4.4 IMMUNOHISTOCHEMISTRY 
Endometrial Tregs were also studied using immunohistochemistry (IHC). 
4.4.1 SAMPLES 
Samples for the IHC part of the study included endometrium from participants in flow 
cytometry experiments (n = 40) and additional samples identified from recent pathology 
archives at RPAH (n = 48). Women from which samples were identified in archival 
pathology adhered to the same inclusion and exclusion criteria as flow cytometry participants 
(detailed in section 4.2.1). For some participants in flow cytometry experiments, endometrial 
samples suitable for IHC were not available (n = 10). 
 
Samples were staged by an experienced gynaecological histopathologist according to the 
histological appearance of the endometrium. Of women with endometriosis (n = 61), 5 were 
in menstrual, 28 in proliferative and 28 in the secretory phase of the menstrual cycle. Of 
women without endometriosis (n = 27), 4 women were in menstrual, 12 in proliferative and 
11 in the secretory phase at the time of sample collection.  
 
4.4.2 TISSUE PROCESSING 
4.4.2.1 FIXATION 
Tissue samples were fixed in 10 % neutral-buffered formalin to preserve tissue components 
and morphology (Boenisch, 2001). After fixation, tissue samples were dehydrated by alcohol, 
cleared of dehydrating agents with xylene and infiltrated with paraffin wax according to a 
standardised protocol. Fixed samples were embedded into a paraffin block to provide 
structural support and allow sectioning for visualisation (Miller et al., 2001). 
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4.4.2.2 TISSUE SECTIONING 
Paraffin embedded tissue samples were cooled to -5 °C on a cold plate (Leica EG1150 C, 
Leica Microsystems Nussloch GmbH, Germany) and cut at 4 μm on a manually operated 
rotary microtome (Leica RM 2135, Leica Microsystems Nussloch GmbH, Germany). Cut 
sections were mounted on glass slides (IHC Microscope Slides, FLEX; Dako, Denmark) and 
dried in a dehydrating oven at 60 °C for 1 hour. 
 
4.4.2.3 DEPARAFFINISATION AND REHYDRATION 
Xylol is an organic solvent capable of dissolving wax. Dried slides were allowed to cool after 
removal from the oven. Slides were deparaffinised with xylol twice (5 minutes each) and 
rehydrated with decreasing strength of alcohol for two minutes each (100 % alcohol twice,  
95 % alcohol and 70 % alcohol) and slow running tap water for two minutes.   
 
4.4.2.4 ANTIGEN RETREIVAL 
During tissue fixation and paraffin embedding, partial or complete loss of immune-reactivity 
can occur for many antigens due to changes in epitope structure which masks the epitope. 
Antigen retrieval “unmasks” or exposes epitopes by breaking down cross-links between 
proteins formed during fixation and reversing some of the antigen denaturation caused by 
fixation and paraffin processing (Miller et al., 2001, Ramos-Vara, 2005) . Antigen retrieval 
can be performed by proteolytic digestion or heat treatment in a buffer solution (heat-induced 
antigen/epitope retrieval, HIER) (Ramos-Vara, 2005).  
In this project, HIER was performed on tissue sections for antigen retrieval. A working 
solution was prepared by diluting 4 mL of the Antigen Target Solution pH 9 (x50 
concentrate; Dako, Denmark) in 196 mL distilled water. The working solution was pre-heated 
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in a water bath to 95-99 ºC. Slides were placed in the preheated antigen retrieval solution and 
incubated for 20 minutes at 95-99 ºC. After HIER, sections were cooled to room temperature 
in the retrieval solution (20 minutes) and thoroughly washed under slow-running tap water 
for 2-3 minutes. Slides were immersed in wash buffer (discussed in section 4.4.3.1) for 10 
minutes to reduce the surface tension prior to IHC staining.
 
4.4.3 AUTOSTAINER 
In this project, an automated slide processing system Dako Autostainer Plus Universal 
Staining System (Dako, Denmark) was used. It consists of a slide processor and dedicated 
desktop computer and can stain 48 slides simultaneously. The reagent, reagent dispense 
volume and reagent dispense location were individually programmed for each slide with the 
autostainer. For all staining runs, the dispense volume was set at 100 μL per dispense 
location. The specific reagent dispense locations were individually selected for each slide to 
ensure the reagent covered the total tissue area.  
 
4.4.3.1 WASH BUFFER 
Wash buffers remove non-specifically bound proteins in specimens to reduce or eliminate 
background. In this project, buffer was prepared by diluting Wash Buffer concentrate (20x; 
Dako, Denmark), a Tris-buffered saline solution containing Tween 20 with pH 7.6 (+ 0.1), in 
deionised water. Buffer rinse steps were programmed on the Autostainer between each 
reagent step. 
 
4.4.3.2 BLOCKING
Positive staining that is not due to antigen-antibody binding is called ‘non-specific’ 
background staining. This non-specific staining can be eliminated or reduced by blocking 
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steps. Endogenous enzymatic activity is strongly present on a number of cells and tissues. 
The presence of endogenous peroxidase and alkaline phosphatase (AP) can obscure specific 
staining of the target antigen (Gao et al., 2008). Dual Endogenous Enzyme Block (DEEB; 
Dako, Denmark) was used to inhibit endogenous peroxidase and AP. After an initial buffer 
wash, the Autostainer was programmed with a 10 minute DEEB incubation period.  
4.4.3.3 ANTIBODY 
In this project, a monoclonal mouse anti-human Foxp3 antibody (clone 236A/E7, Abcam 
Cambridge, UK) at a dilution of 1:100 was used to identify Tregs. The antibody was diluted 
in Antibody Diluent (Dako, Denmark) which comprised of Tris HCL buffer with a stabilising 
protein and a preservative. The Autostainer was programmed to incubate the slides with 
Foxp3 antibody for 30 minutes.  
4.4.3.4 AMPLIFIER 
EnVision FLEX+ Mouse LINKER (Dako, Denmark) was used as an amplifying agent. It 
amplifies the signal from mouse antibodies 4-5 fold compared to regular staining with 
EnVision alone. Following primary antibody incubation, amplifier was applied for 30 
minutes. 
 
4.4.3.5 DETECTION SYSTEMS 
EnVision+ Dual Link System- Horseradish Peroxidise (HRP) (Dako, Denmark) was used as 
the detection system. This system is based on a dextran back-bone to which a large number of 
HRP molecules are conjugated to secondary antibodies. The goat anti-mouse and anti-rabbit 
Igs are purified and coupled with peroxidise-labelled polymers in Tris-HCl buffer and 
stabilising protein and anti-microbial agents are added. The anti-mouse antibodies in the 
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system reacted with the immunoglobulins used in this project. EnVision was applied for 30 
minutes. 
 
4.4.3.6 VISUALISATION 
Diaminobenzidine+ (DAB+) chromogen was used for visualisation with this staining. The 
DAB working solution was prepared by thoroughly mixing 1 drop of DAB+ Chromogen per 
1 mL of Substrate Buffer (Dako, Denmark). DAB+ was applied for 10 minutes and produced 
brown end-product at the site of the target antigen.  
After immunohistochemical staining was complete, slides were rinsed thoroughly with tap 
water.   
 
4.4.3.7 PROTOCOL 
Staining was performed on the Autostainer as follows:  
1. Wash buffer rinse  
2. DEEB - 10 minutes  
3. Wash buffer rinse  
4. Mouse monoclonal anti-human Foxp3 antibody - 30 minutes 
5. Wash buffer rinse  
6. EnVision FLEX+ Mouse LINKER - 30 minutes  
7. Wash buffer rinse  
8. EnVision+ Dual Link System-HRP - 30 minutes  
9. Wash buffer rinse 
10. Wash buffer rinse  
11. DAB - 10 minutes  
12. Wash buffer rinse 
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4.4.3.8 POSITIVE AND NEGATIVE CONTROLS  
Positive and negative endometrial controls were used as part of each staining run. Positive 
controls were endometrial tissue known to contain Foxp3+ cells. Antibody diluent was used, 
instead of the primary antibody, for negative controls in each Autostainer run. All staining 
with diluent controls was negative.  
 
4.4.4 COUNTERSTAINING AND COVER SLIPPING 
Slides were counterstained with Mayers haematoxylin, a blue nuclear stain, for assessment of 
tissue morphology. Slides were quickly dipped in Mayers haematoxylin (approximately 1 
second) and washed in tap water until the water ran clear. Slides were blued in hot tap water 
for 15 seconds. 
 
After counterstaining, slides were dehydrated with increasing concentrations of alcohol for 2 
minutes each (70 % alcohol, 95 % alcohol and 100 % alcohol twice), placed in xylol (2 x 3 
minutes) and coverslipped with Ultramount (Fronine Pty Ltd, Australia).  
 
4.4.5 SLIDE ANALYSIS 
Slides were examined initially under low magnification with the Olympus BX51 microscope 
(Olympus, Japan). Cell counting was performed under 400x magnification. Fields of view 
were captured using an Olympus DP70 digital camera with Image Pro Plus Discovery 
Software (Media Cybermetics Japan). Where possible, 20 fields of view were analysed for 
each sample. In samples where the tissue was not large enough, as many fields of view as 
could fit within the tissue area were captured (overall mean number of fields of view captured 
= 11; range 5 to 20).  
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Tregs were identified by mid to dark brown staining of round, oval or bean-shaped nuclei 
which ranged from 3 to 4 µm in size (Figure 4.10). Treg counting was performed blinded to 
the presence or absence of endometriosis and the gynaecological histopathology endometrial 
dating report. Treg counting was validated by two investigators performing blinded counts on 
all fields of view from 10 tissue specimens. The Intraclass correlation coefficient for the two 
investigators counts was 0.95 (95 % confidence interval 0.93–0.96; n = 325; p = < 0.001).
 
 
Figure 4.10. Foxp3 were identified by mid to dark brown staining of round or oval shaped Treg nuclei 
under 400x magnification.    
 
4.4.6 STATISTICAL METHODS 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) 21.0 software. One-Sample Kolmogorov-Smirnov Test was used to determine 
distribution of variables. Age was normally distributed in all groups and was analysed using 
the independent sample t-test. Data was either skewed or calculated as percentages for other 
variables, therefore, non-parametric statistical testing was performed (Mann–Whitney U-test 
denoted by W U z). Statistical analysis using Kruskal–Wallis test (denoted by H) was 
83 
 
 
 
conducted to determine Treg densities across the menstrual cycle. The correlation between 
immune cell densities and age of participants was determined by applying Pearson correlation 
test and Treg counting by two blind investigators by using Intraclass correlation coefficient. 
Differences between groups were considered to be statistically significant at p-values of less 
than 0.05. 
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CHAPTER 5: RESULTS 
 
5.1 FLOW CYTOMETRY 
This chapter presents the results of multicolour flow cytometric analysis of peripheral blood 
and endometrial leukocytes from women with and without endometriosis. 
 
5.1.1 AGE DISTRIBUTION OF PATIENTS 
Initial analysis was conducted to investigate age distribution and variation between women 
with and without endometriosis and women with and without infertility. No significant 
variation was observed in age between women with and without endometriosis (mean age ± 
SD; 34.5 ± 5.3 yrs versus 37.3 ± 6, respectively). Similarly, there was no statistically 
significant difference in age between fertile (35.3 ± 8.8) and infertile (36.1 ± 4.6) women. 
  
The participants’ age did not appear to correlate to the numbers of circulating or endometrial 
Tregs, CD4+ cells and live lymphocytes.  
 
5.1.2 BLOOD IMMUNE CELL CHANGES IN WOMEN WITH AND WITHOUT 
ENDOMETRIOSIS 
Peripheral blood Tregs, CD4+ lymphocytes and percentages of live lymphocytes were 
assessed between women with and without endometriosis, throughout the menstrual cycle 
(Table 5.1). 
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Table 5.1. Median densities and interquartile ranges of blood Tregs, CD4+ cells and live lymphocytes in 
the menstrual cycle in women with and without endometriosis.
 
    Tregs                 CD4+                    Live lymphocytes 
         Control vs Endo                          Control vs Endo                             Control vs Endo 
 
Overall    4.7 (2.3) vs 4.4 (3.0)          43.9 (14.1) vs 39.8 (13.3)             76.3 (20.2) vs 81.9 (17.0) 
P    5.7 (3.2) vs 4.9 (2.2)           43.4 (18.9) vs 43.8 (13.0)             76.1 (28.5) vs 89.7 (22.4) 
S    4.0 (2.6) vs 5.0 (4.1)          43.7 (14.7) vs 35.7 (18.0)             79.8 (24.1) vs 87.5 (23.8) 
 
Results represented as median (IQR). Menstrual phase results not shown due to insufficient numbers for 
statistical analysis. P = Proliferative, S = Secretory.  
 
Tregs  
In women without endometriosis, Treg median densities showed little variation throughout 
the menstrual cycle (Figure 5.1 A), with numbers being lowest in the secretory phase of the 
normal cycle.  
In endometriosis, Treg densities also showed limited variation throughout the cycle. The 
density of Tregs, however appeared to be lowest during the menstrual phase. Treg density 
gradually increased through the proliferative phase and peaked in the secretory phase (Figure 
5.1 A). However these changes were not found to be statistically significant.   
 
CD4+ cells 
Significant differences were not observed in the densities of CD4+ cells throughout the 
menstrual cycle or between women with and without endometriosis (Figure 5.1 B).    
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Percentages of live lymphocytes 
Slight variations were observed in the percentages of live lymphocytes throughout the 
menstrual cycle. In women without endometriosis, the median density of live lymphocytes 
appears to be reduced in the menstrual and proliferative phases. In women with 
endometriosis, median density of circulating live lymphocytes followed a similar pattern, 
although the density of live lymphocytes appeared to be higher in women with endometriosis 
compared to controls across all phases of the menstrual cycle (Figure 5.1 C).      
 
 
  
 
Figure 5.1. Comparison of median numbers of blood Tregs, CD4+ cells and live lymphocytes in all phases 
of the menstrual cycle between women with and without endometriosis (M = Menstrual, P = Proliferative, 
S = Secretory).  
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5.1.3 ENDOMETRIAL IMMUNE CELL CHANGES IN WOMEN WITH AND 
WITHOUT ENDOMETRIOSIS 
Table 5.2 demonstrates Tregs, CD4+ cells and live lymphocytes proportions in women with 
and without endometriosis across different phases of the menstrual cycle.  
 
Table 5.2. Median densities and inter-quartile ranges of endometrial Tregs, CD4+ cells and live 
lymphocytes in the menstrual cycle in women with and without endometriosis.  
 
    Tregs         CD4+              Live lymphocytes 
         Control vs Endo                   Control vs Endo                               Control vs Endo 
 
Overall         8.1 (4.6) vs 9.6 (8.2)             22.5 (7.5) vs 24.2 (9.1)        71.6 (30.4) vs 77.7 (17.4) 
P        8.2 (27.4) vs 9.9 (8.3)           23.4 (4.6) vs 28.4 (10.1)                58.5 (31.3) vs 83.9 (17.1) 
S        6.7 (7.3) vs 7.6 (7.8)             21.3 (9.1) vs 21.8 (7.6)                  79.5 (21.8) vs 76.9 (12.7)  
 
Results represented as median (IQR). Menstrual phase results not shown due to small number of 
participants. P = Proliferative, S = Secretory. 
 
Tregs 
In women without endometriosis, density of endometrial Tregs did not significantly change 
during the menstrual cycle. During the proliferative phase of the normal cycle, Treg density 
greatly varied (Median = 8.8 – 45.1). In women with endometriosis, Treg density was 
observed to decline from menstrual through to secretory phase, although these differences 
were not found to be statistically significant (Figure 5.2 A).      
CD4+ cells 
In both women with and without endometriosis, CD4+ cells appeared to follow a similar 
pattern throughout the phases of the menstrual cycle. An increase in CD4+ cells occurred 
from menstrual to the proliferative phase, followed by a decline in the secretory phase. A 
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strong trend suggests that endometrial CD4+cell declined from proliferative to the secretory 
phase in women with endometriosis (W U z = -1.9; p = 0.06). In women without the disease, 
this reduction from proliferative to secretory phase was not so marked (Figure 5.2 B).  
 
Percentages of live lymphocytes 
While there were no statistically significant differences in the percentages of live 
lymphocytes throughout the menstrual cycle, it was interesting to note that in women without 
endometriosis, percentages of live lymphocytes were lowest in the proliferative phase. 
However, in endometriosis, percentages of live lymphocytes gradually declined from 
menstrual through to secretory phase of the menstrual cycle (Figure 5.2 C).      
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Figure 5.2. Comparison of median numbers of endometrial Tregs, CD4+ cells and live lymphocytes in all 
phases of the menstrual cycle between women with and without endometriosis (M = Menstrual, P = 
Proliferative, S = Secretory). 
 
5.1.4 BLOOD IMMUNE CELL CHANGES IN FERTILE AND INFERTILE WOMEN  
Peripheral blood Tregs, CD4+ lymphocytes and percentages of live lymphocytes were 
compared between fertile and infertile women throughout the phases of the menstrual cycle 
(Table 5.3).  
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Table 5.3. Median densities and interquartile ranges of blood Tregs, CD4+ cells and live lymphocytes in 
the menstrual cycle in fertile and infertile women.  
 
    Tregs               CD4+                    Live lymphocytes 
      Fertile vs Infertile                        Fertile vs Infertile                          Fertile vs Infertile 
 
Overall     5.5 (1.5) vs 3.8 (3.2)     45.1 (16.3) vs 42.2 (14.9)  76.3 (21.3) vs 81.9 (18.0) 
P     5.6* vs 4.4 (2.7)  44.1* vs 43.8 (10.0)  63.4* vs 89.9 (19.4)  
S     4.2* vs 4.8 (3.5)  45.1* vs 41.2 (18.0)  82.1* vs 88.2 (19.6) 
 
Results represented as median (IQR). Menstrual phase results not shown due to small number of 
participants. P = Proliferative, S = Secretory, * IQR missing due to small number of participants.  
 
Tregs 
In fertile and infertile women, densities of circulating Tregs showed little variation across the 
menstrual cycle (Figure 5.3 A).  
CD4+ cells     
Significant differences were not observed in CD4+ cells throughout the menstrual cycle or 
between fertile and infertile women (Figure 5.3 B).     
Percentages of live lymphocytes
There was a strong trend for decrease in percentages of live lymphocytes in fertile women 
during the proliferative phase of the cycle compared to infertile women (W U z = -1.9; p = 
0.05; Figure 5.3 C). This reduction also occurred during the menstrual and secretory phases 
in fertile patients compared to infertile women, although level of significance was not 
reached. In infertile patients, percentages of live lymphocytes showed very little variation 
throughout the menstrual cycle  
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Figure 5.3. Comparison of median numbers of blood Tregs, CD4+ cells and live lymphocytes in all phases 
of the menstrual cycle between fertile and infertile women (M = Menstrual, P = Proliferative, S = 
Secretory, *p < 0.05). 
 
5.1.5 ENDOMETRIAL IMMUNE CELL CHANGES IN FERTILE AND INFERTILE 
WOMEN  
Table 5.4 summarises endometrial Tregs, CD4+ lymphocytes and percentages of live 
lymphocytes in fertile and infertile women throughout the phases of the menstrual cycle.  
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Table 5.4. Median densities and interquartile ranges of endometrial Tregs, CD4+ cells and live 
lymphocytes in the menstrual cycle between fertile and infertile women. 
 
    Tregs               CD4+                    Live lymphocytes 
      Control vs Infertile                  Control vs Infertile                Control vs Infertile 
 
Overall      11.8 (7.6) vs 8.0 (6.0)  22.5 (4.8) vs 3.8 (9.0)    67.5 (20.8) vs 83.3 (18.4)  
P      17.7* vs 8.3 (3.1)  22.5* vs 27.7 (8.7)  57.0* vs 84.2 (22.7) 
S      11.6 * vs 6.8 (9.9)      23.9 * vs 19.1 (7.7)  76.5* vs 76.8 (18.4)  
 
Results represented as median (IQR). Menstrual phase results not shown due to small number of 
participants. P = Proliferative, S = Secretory, * IQR missing due to small number of participants.  
Tregs 
A significant increase in endometrial Treg populations were observed in fertile women, 
compared to infertile women during the proliferative phase (W U z = -2.3, p = 0.02). In fertile 
women, Treg density appeared to vary throughout the cycle with a peak in the proliferative 
phase of the cycle. In infertile women, very little variation was observed in Treg populations 
throughout the menstrual cycle (Figure 5.4 A). 
CD4+ cells 
CD4+ cells were significantly reduced in fertile compared to infertile women during the 
proliferative phase of the cycle (W U z = -2.3, p = 0.02). In infertile women, there was a very 
strong trend for CD4+ populations to vary throughout the menstrual cycle (H = 5.8; p = 0.05). 
CD4+ numbers in these women peaked in the proliferative phase but reached their lowest 
levels in the secretory phase (Figure 5.4 B).    
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Percentages of live lymphocytes
A significant reduction in the percentages of live lymphocytes occurred in fertile patients 
during the proliferative phase of the cycle compared to infertile participants (W U z = -2.1; p 
= 0.03). No differences were noted between fertile and infertile patients during other phases 
of the cycle. In fertile women, endometrial live lymphocyte numbers decreased from 
menstrual to the proliferative phase, before rising again in the secretory phase. In infertile 
women, percentages of live lymphocytes were relatively constant throughout the menstrual 
cycle (Figure 5.4 C).      
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Figure 5.1.4. Comparison of median endometrial numbers of Tregs, CD4+ cells and live lymphocytes in all 
phases of the menstrual cycle between fertile and infertile women (M = Menstrual, P = Proliferative, S = 
Secretory,* p value < 0.05).  
 
5.1.6 BLOOD IMMUNE CELL CHANGES IN ENDOMETRIOSIS-ASSOCIATED 
INFERTILITY  
Circulating Tregs, CD4+ lymphocytes and percentages of live lymphocytes were analysed in 
fertile and infertile women with and without endometriosis during the menstrual cycle (Table 
5.5).  
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Densities and IQRs of circulating Tregs, CD4+ cells and live lymphocytes in infertile women 
without endometriosis and fertile and infertile women with endometriosis are summarised in 
Table 5.5. Data from the menstrual phase is not shown due to extremely small sample size 
during this time of the cycle. 
  
Table 5.5. Median densities and interquartile ranges of blood Tregs, CD4+ cells and live lymphocytes in 
the menstrual cycle in fertile and infertile women with and without endometriosis.  
 
      Proliferative  N  Secretory N  
 
Tregs 
No endo, Infertile  4.7*   3  4.1 (2.6)  7 
Endo, Fertile     5.7*   2  4.2*  3 
Endo, Infertile     4.2 (1.5)   11  5.6 (5.9)  12 
CD4+ 
No endo, Infertile   43.9*   3  43.5 (14.7) 7 
Endo, Fertile     47.6*   2  45.1*  3 
Endo, Infertile     42.5 (15.3)  11  34.4 (14.7) 12 
Live lymphocytes    
No endo, Infertile     71.9*   3  79.0 (14.7) 7 
Endo, Fertile     62.1*   2  82.1*  3 
Endo, Infertile               89.2 (11.5)  11  86.1 (23.8)      12      
Data represented as median (IQR). P=Proliferative, S=Secretory, * No inter-quartile ranges due to small 
number of participants. 
    
Tregs 
Overall, Treg density showed very little variation between fertile and infertile women with 
endometriosis and fertile and infertile women without endometriosis, when all phases of the 
menstrual cycle combined (Figure 5.5 A). During the proliferative and secretory phases, little 
variation was noted between fertile and infertile endometriosis patients (Table 5.5; Figure 5.6 
A).  
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CD4 + cells 
In endometriosis, circulating CD4+ numbers did not differ markedly between fertile and 
infertile women throughout the cycle (Figure 5.5 B). CD4+ cells did not show any marked 
difference between proliferative and the secretory phase, although CD4+ cells were higher in 
fertile women with endometriosis compared to infertile endometriosis patients in the secretory 
phase of the cycle (Figure 5.6 B).  
Percentage of live lymphocytes 
Percentages of live circulating lymphocytes appeared to be lower in women with 
endometriosis, who were fertile, compared to those who were infertile (Figure 5.5 C). While 
this difference was observed in both proliferative and secretory phases, it was significant only 
in the proliferative phase of the cycle (W U z = -2.1; p = 0.03; Figure 5.6 C). No significant 
differences were observed between the percentages of live lymphocytes between fertile and 
infertile controls. 
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Figure 5. 5. Overall median densities of blood Tregs, CD4+ cells and live lymphocytes and their 
comparison between fertile and infertile women with and without endometriosis. 
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Figure 5.6. Median densities of blood Tregs, CD4+ cells and live lymphocytes in fertile and infertile 
women with endometriosis in the proliferative (P) and secretory (S) phases (* p value < 0.05).  
 
5.1.7 ENDOMETRIAL IMMUNE CELL CHANGES IN ENDOMETRIOSIS-
ASSOCIATED INFERTILITY 
Median endometrial densities and IQRs of live lymphocytes, CD4+ cells and Tregs were 
analysed in fertile and infertile women with endometriosis and infertile women without the 
disease which are summarised in Table 5.6.  
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Table 5.6. Median densities and interquartile ranges of endometrial Tregs, CD4+ cells and live 
lymphocytes in the menstrual cycle in fertile and infertile women with and without endometriosis.  
 
      Proliferative  N  Secretory N 
 
Tregs 
No endo, Infertile  8.1*   3  6.5 (7.3)  6 
Endo, Fertile     17.8*   2  11.6*  3 
Endo, Infertile     8.9 (6.0)   6  7.1 (14.3) 6 
CD4+ 
No endo, Infertile   24.2*   3  21.3 (9.1) 6 
Endo, Fertile     26.1*   2  23.9*  3 
Endo, Infertile     28.8 (11.3)  6  18.7 (11.2) 6 
Live lymphocytes    
No endo, Infertile     58.9*   3  79.5 (21.8) 6 
Endo, Fertile     51.4*   2  76.5*  3 
Endo, Infertile               86.9 (6.8)  6  78.5 (15.7)     6      
 
Data represented as median (IQR). P=Proliferative, S=Secretory, * No inter-quartile ranges due to small 
number of participants. 
 
Tregs 
There was no significant difference in Treg cells populations between fertile and infertile 
women with endometriosis or between the infertile women without endometriosis. Tregs 
appeared to be increased in fertile controls compared to the other groups (Figure 5.7 A). In 
women with endometriosis who were fertile, Treg density appeared to be higher during the 
proliferative phase in comparison to infertile endometriosis patients. However this difference 
did not reach statistical significance (Figure 5.8 A). Similarly, no significant difference was 
noted between fertile and infertile endometriosis patients during the secretory phase of the 
cycle. 
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CD4+ cells  
Overall endometrial density of CD4+ cells showed little variation between fertile and infertile 
women with endometriosis (Figure 5.7 B). In infertile endometriosis patients, CD4+ cells 
were significantly reduced from proliferative to the secretory phase (W U z = -2.2; p = 0.03; 
Figure 5.8 B). While a similar pattern was noted in fertile women with endometriosis, this 
reduction did not reach level of statistical significance. 
 
Percentage of live lymphocytes 
Overall percentages of live endometrial lymphocytes did not significantly vary between fertile 
and infertile controls or in fertile endometriosis patients; however they appeared to be 
increased in infertile women with endometriosis (Figure 5.7 C). During the proliferative phase 
of the cycle, percentages of live lymphocytes were significantly increased in infertile 
endometriosis patients, compared to fertile women with endometriosis (W U z = -2.1; p = 
0.03). This difference was not observed in the secretory phase (Figure 5.8 C).   
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Figure 5.7. Overall median densities of endometrial Tregs, CD4+ cells and live lymphocytes and their 
comparison between fertile and infertile women with and without endometriosis.  
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Figure 5.8. Median densities of endometrial Tregs, CD4+ cells and live lymphocytes in fertile and infertile 
women with endometriosis in the proliferative (P) and secretory (S) phases (* p value < 0.05). 
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5.2 IMMUNOHISTOCHEMICHEMISTRY  
Foxp3+ Treg counts were analysed between fertile and infertile women with and without 
endometriosis.  
 
5.2.1 AGE DISTRIBUTION  
Age distribution did not statistically differ between women with endometriosis (mean age ± 
SD = 35.7 ± 7.0 yrs) and those without the disease (33.8 ± 8.0). Similarly, no differences in 
age distribution were noted between fertile (35.7 ± 8.0) and infertile (35.5 ± 7.0) women. 
Furthermore, the age of participants did not appear to significantly correlate with Foxp3 
density in the endometrium.     
 
5.2.2 FOXP3+ CELLS IN WOMEN WITH AND WITHOUT ENDOMETRIOSIS  
Median densities of Foxp3+ cells in women with endometriosis and controls were analysed 
across different phases of the menstrual cycle. Results (presented as median and interquartile 
ranges of Foxp3+ cells per mm
2
) are shown in Table 5.7.  
 
Table 5.7. Median densities and interquartile ranges of Foxp3 in the menstrual cycle in women with and 
without endometriosis. 
   Controls   N  Endometriosis  N
 
Menstrual  0.3 (5.2)   4  1.5 (8.3)   5 
Proliferative  1.4 (3.8)   12  1.4 (4.8)   28 
Secretory  1.5 (5.5)   11  2.1 (8.1)   28
Data represented as median (IQR), * IQR not shown due to small sample size in the group. 
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Foxp3+ cells during the normal menstrual cycle 
No significant differences were observed in Foxp3+ cell density during the phases of the 
menstrual cycle. 
 
Foxp3+ cells in endometriosis 
Large variations in Foxp3+ cell density were noticed in the secretory phase (0-18.7 per mm
2
). 
No significant differences were noted in Foxp3 cell density during the menstrual cycle of 
women with endometriosis. Similarly there were no significant differences between women 
with and without endometriosis (Figure 5.9). 
 
 
 
Figure 5.9. Comparison of median densities of Foxp 3+ cells between women with and without 
endometriosis (M = Menstrual, P = Proliferative, S = Secretory).  
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5.2.3 FOXP3+ CELLS IN FERTILE AND INFERTILE WOMEN 
Median densities of Foxp3+ cells in fertile and infertile women were analysed across 
different phases of the menstrual cycle. The results are summarised in Table 5.8.  
 
Table 5.8. Median densities and interquartile ranges of Foxp3+ cells in the menstrual cycle in fertile and 
infertile women. 
   Fertile    N  Infertile   N
Menstrual  0*   3  1.8*   3  
Proliferative  2.3 (2.4)   12  1.4 (4.8)   26  
Secretory  1.3 (3.1)   11  3.2 (7.7)   22 
Data represented as median (IQR), * IQR not shown due to small sample size. 
  
Foxp3+ cells in fertile and infertile women 
Foxp3+ cell numbers did not appear to vary markedly in the menstrual cycle in fertile and 
infertile women. However, the range in cell densities greatly varied in infertile women during 
the proliferative (0 - 8.6 per mm
2
) and secretory phase (0 – 11.8 per mm2) and such variations 
were not noted in the menstrual phase. No significant differences were seen between fertile 
and infertile women during the menstrual cycle (Figure 5.10). 
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Figure 5.10. Comparison of median densities of Foxp3+ cells between fertile and infertile women in the 
menstrual cycle (M = Menstrual, P = Proliferative, S = Secretory).  
 
5.2.4. FOXP3+ CELLS IN ENDOMETRIOSIS-ASSOCITED INFERTILITY  
Cell densities were analysed across different phases of the menstrual cycle in fertile and 
infertile women with and without endometriosis. These results are summarised in Table 5.9.   
 
Table 5.2.2. Median densities and interquartile ranges of Foxp3+ cells in the menstrual cycle in fertile and 
infertile women with and without endometriosis. 
   Menstrual    N Proliferative N     Secretory        N 
 
Infertile, Endo         1.7 (5.2)  4 1.3 (6.3)  17     2.6 (10.2)      15 
Fertile, Endo  *  0 1.9 (2.6)  9     1.2 (3.3)      12 
Infertile, Control  *  0 0.9 (3.8)  8     6.1 (8.3)      6 
Fertile, Control    1.7*  2 2.0 (9.7)  4     *       0 
Data represented as median (IQR), * Data not shown due to small sample size. 
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Foxp3+ cells in infertile women without endometriosis 
Foxp3+ cell numbers appeared to increase from proliferative to the secretory phase in 
infertile women without endometriosis (Figure 5.11). This difference, however, was not 
found to be statistically significant. In fertile women without endometriosis, no large 
variations in Treg counts were observed between menstrual and the proliferative phase.  
 
Foxp3+ cells in fertile and infertile women with endometriosis 
Median density of Foxp3+ cells in infertile women with endometriosis was slightly higher in 
the secretory phase compared to menstrual and the proliferative phases. Range in cell 
densities varied greatly in the secretory phase in infertile women with endometriosis (0 – 21.2 
per mm
2
). Overall, Foxp3+ cells did not show marked variations throughout the menstrual 
cycle in fertile and infertile women with endometriosis. 
 
 
 
Figure 5.11. Density of Foxp3+ cells in fertile and infertile women with and without endometriosis 
throughout the menstrual cycle (M = Menstrual, P = Proliferative, S = Secretory).  
  
 
108 
 
 
 
CHAPTER 6: DISCUSSION 
 
6.1 INTRODUCTION 
This project aimed to characterise Treg populations in blood and the endometrium in women 
with endometriosis and associated infertility during the menstrual cycle. In order to 
characterise Treg populations, this thesis also investigated CD4+ T cells and live 
lymphocytes during the normal cycle, in endometriosis and infertility. The results of this 
project show that density of endometrial and circulating live lymphocyte populations are 
increased in endometriosis, infertility and endometriosis-associated infertility compared to 
controls. The numbers of proliferative phase Tregs in the endometrium are also increased in 
fertile compared to infertile women. 
 
6.2 NORMAL MENSTRUAL CYCLE 
 
6.2.1 DECREASED SURVIVAL OF LYMPHOCYTES FROM THE 
PROLIFERATIVE PHASE  
During the normal cycle, the numbers of endometrial live lymphocytes appeared to show 
significant differences, decreasing from menstrual to the proliferative phase, before rising 
again in the secretory phase. This pattern was also noted amongst the fertile group of patients, 
suggesting that reduced viability of lymphocytes in the proliferative phase may also play a 
role in uterine receptivity. The numbers of immune cells show day-to-day variations in the 
endometrium which are important to carry out normal functions such as menstruation, 
endometrial remodelling and preparation for embryo implantation (Salamonsen and 
Lathbury, 2000). Previous studies show generally decreased numbers of immune cells in the 
proliferative phase (Mettler et al., 1996, Salamonsen and Lathbury, 2000). Reduced numbers 
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of endometrial immune cells in the early and late parts of the proliferative phase may serve 
different purposes. In the early proliferative phase, decreased immune cell numbers may 
allow regeneration of the endometrial glandular and stromal components after menstrual 
shedding (Finn, 1986) while decreased numbers of immune cells in the late proliferative 
phase may be in preparation for embryo implantation (Arruvito et al., 2007 , Guerin et al., 
2009). 
 
The findings of the present study indicate that lymphocyte viability may also be reduced in 
blood during the normal proliferative phase. This study is the first to date to demonstrate 
leukocyte viability differences during the menstrual cycle. Current evidence suggests that 
lymphocyte count in blood is reduced in proliferative compared to the menstrual and the 
secretory phases (Rosemary et al., 2014). Earlier, Mathur et al. (1979) had performed day-to-
day analysis of blood lymphocytes and concluded that lymphocyte count in blood negatively 
correlates with serum oestradiol levels (Mathur et al., 1979). Since oestradiol levels peak in 
the late proliferative phase, it was suggested that reduced numbers of lymphocytes at the time 
of ovulation may be in prepration to suppress immuno-reactivity during embryo implantation 
(Mathur et al., 1979).  
 
Our findings of generalised reduced viability of lymphocytes in the proliferative phase are an 
important observation. These changes may be vital not only to allow for normal immune cell 
turnover, but play active roles in preparation for implantation of the embryo, should 
pregnancy occur.  
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6.2.2 INFLUX OF IMMUNE CELLS AND INCREASED LYMPHOCYTE VIABILITY 
IN THE SECRETORY PHASE 
During the normal cycle, the viability of lymphocytes appeared to increase again in the 
secretory phase. Previous studies have noted marked endometrial influx of most of the 
immune cell types in the secretory phase (Mettler et al., 1996, Salamonsen and Lathbury, 
2000). Recruitment of immune cells in the secretory phase may be essential to prepare for 
possible implantation and menstruation if implantation does not occur (Salamonsen, 1998, 
Salamonsen and Lathbury, 2000). Although the numbers of T lymphocyte sub-populations 
fluctuate in the secretory phase (Klentzeris et al., 1995, Mettler et al., 1996), endometrial total 
T lymphocyte count shows little variation in the menstrual cycle between late proliferative 
and the secretory phase (Mettler et al., 1996). Since the viability of lymphocytes has not been 
analysed previously, it can be suggested that recruitment of live immune cells in the secretory 
phase may be in preparation to target shed fragments during menstruation. Increased numbers 
of live lymphocytes during the normal secretory phase were also observed in blood. These 
findings of increased numbers of live lymphocytes in the secretory phase may be part of a 
generalised immune response required in preparation for menstruation, during which time 
immune cells play important roles in targeting shed fragments, allowing for regeneration and 
repair of the endometrium (Salamonsen, 1998).  
 
6.2.3 VARIATIONS IN CD4+ CELL COUNT 
The findings from this study showed that during the normal cycle, endometrial CD4+ T cell 
numbers vary minimally between the proliferative and secretory phases. Similar findings 
were observed in fertile participants of the study. Low variability in the numbers of 
endometrial CD4+ cells during the peri-implantation period is in line with a previous finding 
of little variation in endometrial CD4+ cell count between the proliferative and secretory 
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phases (Mettler et al., 1996). Despite no large variations in numbers, cytokine production by 
CD4+ sub-populations is altered in early pregnancy (Veenstra et al., 2003) in preparation for 
implantation. Since the increased numbers of endometrial CD4+ cells during the peri-
implantation period have been linked to pregnancy loss (Lachapelle et al., 1996, Bartha et al., 
2000), minimal variations in CD4+ cell count during the menstrual cycle appear to support 
implantation of embryo.  
 
6.2.4 Tregs IN THE SECRETORY PHASE 
Flow cytometric analysis demonstrated a decrease in the numbers of Tregs during the 
secretory compared to the proliferative phase of the normal cycle. Similar but more 
pronounced differences were observed in the endometrium of fertile women. These findings 
are in accordance with previously published data, which has shown that normally, 
endometrial Tregs numbers dramatically decrease in secretory compared to the proliferative 
phase of the menstrual cycle (Berbic et al., 2010). It has been suggested that higher numbers 
of Tregs in the proliferative phase may suppress other immune cells in preparation for 
possible implantation, while their decline in the secretory phase may be essential in the lead 
up to menstruation to allow other  immune cells to effectively target the shed fragments 
(Berbic et al., 2010, Basta et al., 2010). Although there is no other study that compares the 
numbers of proliferative and secretory phase Tregs in the endometrium, it has been shown 
that women with low numbers of endometrial Tregs are less likely to mediate immune-
tolerance of the fetus and can result in spontaneous pregnancy-loss (Sasaki et al., 2004).  
 
Increased numbers of Tregs were also evident in blood during proliferative compared to the 
secretory phase. These findings were also observed amongst women with proven fertility. 
Previous findings have shown that numbers of Tregs positively correlate with circulating 
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oestradiol levels in fertile women (Arruvito et al., 2007). Serum oestradiol levels peak in the 
late proliferative phase, just before ovulation, which is considered to be important for 
preparation of the endometrium for implantation of the embryo (Groothuis et al., 2007). 
Apart from the endometrial structural changes under the influence of oestradiol, increase in 
Treg count may facilitate implantation of embryo by suppressing pro-inflammatory immune 
cells (Arruvito et al., 2007, Tai et al., 2008).  
  
6.3 ENDOMETRIOSIS 
 
6.3.1 INCREASED SURVIVAL OF LYMPHOCYTES  
In women with endometriosis, a number of significant differences in immune cell viability 
were noted during the menstrual cycle. In these women, an increase in the live lymphocyte 
count occurs in the proliferative phase, during which time leukocyte viability is low in 
women without the disease. It has previously been shown that in endometriosis, the glandular 
and stromal components of the endometrium are more resistant to apoptosis compared to 
women without the disease (Dmowski et al., 2001, Harada et al., 2004, Nishida et al., 2005, 
Nasu et al., 2009). Generally, increased survival of endometrial cells in endometriosis may 
help more viable endometrial cells reach the peritoneal cavity and hence the establishment of 
endometriotic lesions (Vinatier et al., 2000, Sharpe-Timms, 2001, Ulukus and Arici, 2005). It 
is unknown if, in addition to the glandular and stromal cells, immune populations are also 
likely to be more resistant to apoptosis in women with endometriosis compared to controls. 
Increased survival of endometrial live lymphocytes in the proliferative phase in women with 
endometriosis may interfere with endometrial receptivity.  
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Interestingly, the current results indicate that viability of lymphocytes may be increased 
across all phases of the menstrual cycle in blood of women with endometriosis compared to 
women without the disease. It is unclear why there may be increased survival of immune 
cells in blood and how it may influence the endometrial populations. It can be hypothesised 
that there is increased survival of immune cells in women with endometriosis as a result of 
the generalised increased resistance to apoptosis. There is some evidence that certain pro-
inflammatory cytokines, such as IL-8 and TNF-alpha, can promote survival of immune cells 
in women with endometriosis (Kwak et al., 2002, Kyama et al., 2003). Increased levels of 
these cytokines in blood of women with endometriosis (Gazvani and Templeton et al., 2002) 
may contribute to a generalised increase in resistance to apoptosis of immune cells in women 
with endometriosis.  
 
6.3.2 CD4+ CELL COUNT 
In endometriosis, a strong trend suggested that endometrial CD4+ cell proportions are 
increased in the proliferative compared to secretory phase of the cycle. Bulmer et al (1998) 
have previously shown that numbers of endometrial CD4+ lymphocytes do not show large 
variations in endometriosis. In endometriosis, cytokine secretion is altered by CD4+ cells that 
may affect macrophage function (Nasu et al., 2009). It can be hypothesised that an increase in 
numbers of endometrial live CD4+ cells is part of a generalised increase in live lymphocyte 
count that may create a hostile environment interfering with successful implantation and 
contribute to endometriosis-associated infertility.  
 
 6.3.3 Tregs IN THE SECRETORY PHASE 
In women with endometriosis, endometrial Foxp3+ cell numbers appeared to decrease in the 
secretory compared to the proliferative phase. However, endometrial Treg proportions 
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detected by flow cytometry appeared to be higher across all phases of the menstrual cycle in 
women with endometriosis compared to controls. The results from flow cytometric analysis 
are in concordance to previously published data showing that in women with endometriosis, 
endometrial Treg count normally decreases from the proliferative to secretory phase during 
which time Tregs are persistently elevated in endometriosis (Berbic et al., 2010). It was 
previously suggested that failure of the immune system to clear refluxed endometrial tissue 
due to increased suppression by Tregs in the late secretory phase may facilitate their 
implantation in the peritoneal cavity. In addition to changes in Treg count, certain 
endometrial Foxp3 mRNA genetic polymorphisms are over-expressed in endometriosis 
compared to controls that can alter numbers of Tregs and contribute to pathogenesis of the 
disease (André et al., 2011, Barbosa et al., 2012). The findings of the present study did not 
reach statistical significance. This may be explained by smaller numbers of samples in the 
present study. Furthermore, immune cell numbers show day-to-day variations in the 
menstrual cycle and due to small sample size, the present study could not investigate in-phase 
variations (early, mid and late phase). 
 
As in the endometrium, Treg proportions appeared to increase in blood of women with 
endometriosis compared to controls in the secretory phase. Although the numbers of Tregs in 
blood of women with endometriosis have not been studied previously during the secretory 
phase, it has been reported that overall Treg count is increased in women with endometriosis 
compared to controls (Jarosław et al., 2007). It is known that Treg count positively correlates 
with serum oestradiol levels and normally decreases in the secretory phase (Arruvito et al., 
2007). Since endometriosis is an oestrogen-dominant disease, blood Treg proportions in 
endometriosis may appear to increase secondary to increased levels of oestradiol in the 
secretory phase. 
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6.4 INFERTILITY 
 
6.4.1 INCREASED SURVIVAL OF LYMPHOCYTES FROM INFERTILE WOMEN 
In infertile women, there was a significant increase in endometrial proportions of live 
lymphocytes in the proliferative phase compared to fertile controls. Previously it has been 
reported that lymphocyte count is increased in infertile women compared to fertile controls in 
the mid-secretory phase (Stewart-Akers et al., 1998). No such evidence was found in the 
proliferative phase in another study that reported only minimal variations in endometrial 
lymphocyte counts in infertile women (Klentzeris et al., 1994) but this used less advanced 
techniques and did not consider lymphocyte viability. While the viability of endometrial 
lymphocytes has not been determined in infertility previously, it has been shown that peri-
implantation increase in the endometrial immune cell count is associated with an increased 
release of pro-inflammatory cytokines in infertile women (Stewart-Akers et al., 1998). Pro-
inflammatory cells undergo apoptosis in early pregnancy under the influence of cytokines. 
Therefore, disturbances in the intricate balance of pro- and anti-inflammatory cytokines may 
result in rejection of early pregnancy (Reinhard et al., 1998).    
 
In blood, a strong trend suggested increase in proportions of live lymphocytes in infertile 
women in the proliferative phase. The numbers of circulating lymphocytes were previously 
shown not to vary between infertile women and fertile controls (Vujisić et al., 2004), 
However, viability of lymphocytes was not assessed in their study and study participants 
included women undergoing artificial reproductive techniques with hormonal preparations 
which may have altered the cell counts.  
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On the basis of these results, it can be hypothesised that increased survival of blood and 
endometrial lymphocytes in the proliferative phase may contribute to creation of a hostile 
environment for embryo implantation. However, the underlying mechanisms that may 
contribute to increased survival of immune cells in infertility still remain to be further 
investigated.  
 
6.4.2 CD4+ CELLS IN THE PROLIFERATIVE PHASE 
In infertile women, the endometrial CD4+ cell counts were significantly increased during the 
proliferative phase compared to fertile participants. This corresponds with a previous finding 
of increase in the endometrial CD4+ cell count in infertile women in the proliferative phase 
(Klentzeris et al., 1994). An intricate balance of pro-inflammatory (Th-1) and anti-
inflammatory (Th-2) immune cells and cytokines is essential to avoid fetal rejection in early 
pregnancy (Sykes et al., 2012) as increase in the numbers of  endometrial CD4+ cells before 
implantation may interfere with early pregnancy. As CD4+ cells include Th-1 and Th-2 
immune cell populations, further classification of CD4+ populations would be helpful in 
order to elucidate exact implications in infertile women. 
 
6.4.3 Tregs IN INFERTILITY  
In the endometrium, flow cytometric results showed a significant decrease in the numbers of 
Tregs in infertile women during the proliferative phase compared to fertile participants. In 
unexplained infertility, endometrial Treg Foxp3 mRNA expression is decreased in the mid-
secretory phase compared to fertile controls (Jasper et al., 2006). It has been suggested that 
altered Foxp3 expression in infertile women may result in impaired endometrial recruitment 
of Tregs or differentiation of uterine T cells into Tregs (Jasper et al., 2006, André et al., 
2011). Since a pre-ovulatory surge of endometrial Tregs in the proliferative phase is thought 
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to facilitate immune-tolerance for successful implantation (Guerin et al., 2009), a decrease in 
Treg count before implantation may lead to embryo-rejection. Evidence suggests that Tregs 
have more inhibitory effect on Th-1 cells compared to Th-2 cells (Cosmi et al., 2004) and in 
early pregnancy, there is a decrease in Th-1/Th-2 ratio (Doria et al., 2006). Therefore, an 
increase in the numbers of Th-1 immune cells may result in rejection of pregnancy (Guerin et 
al., 2009) as women with early pregnancy loss have reduced numbers of endometrial Tregs 
compared to fertile controls (Sasaki et al., 2004, Arruvito et al., 2007, Yang et al., 2008).   
 
In addition to previous reports of decreased Foxp3 expression during the secretory phase, this 
study indicates that an endometrial immune environment unfavourable to implantation may 
be established earlier in the cycle than previously recognised. Un-moderated immune 
responses in the endometrium during this time would contribute to establishment of an 
endometrial environment unfavourable for implantation. 
 
In blood, Treg numbers appeared to decrease in infertile women compared to fertile 
participants during the proliferative phase. Treg numbers have not been studied in blood in 
infertile women previously but experiments in a mouse model suggest that Treg 
dysregulation in blood may lead to embryo-rejection by Th1-mediated exaggerated maternal 
immune response (Aluvihare et al., 2004). Our results suggest a generalised decrease in the 
numbers of Tregs in the proliferative phase, and thus inefficient immune-suppression, may 
allow for persistent elevation of other immune-cell populations that may in turn create a 
hostile environment, interfering with successful embryo implantation. 
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6.5 ENDOMETRIOSIS-ASSOCIATED INFERTILITY 
 
6.5.1 INCREASED SURVIVAL OF LYMPHOCYTES FROM ENDOMETRIOSIS-
ASSOCIATED INFERTILITY 
The results from this thesis also reveal a number of interesting differences in immune- 
mediated responses in women with endometriosis-associated infertility. In these women, the 
numbers of proliferative-phase endometrial live lymphocytes increased significantly 
compared to women with endometriosis who were fertile. Roles of endometrial lymphocytes 
and their subgroups have not been studied in endometriosis-associated infertility previously. 
It can be hypothesised that increased numbers of live lymphocytes before implantation in 
infertile women with endometriosis alter the endometrial conditions, making them less 
favourable for embryo implantation. As in the endometrium, survival of lymphocytes was 
significantly increased in blood of infertile women with endometriosis compared to fertile 
women with the disease in the proliferative phase. Previously, increased numbers of 
lymphocytes have been observed in blood of infertile women with endometriosis (Badawy et 
al., 1987).  
 
In endometriosis, immune cells may adversely affect fertility by altered cytokine production 
(Dimitriadis et al., 2006, Vassiliadis et al., 2005). Decidualisation is a pre-requisite for 
embryo implantation and endometrial stromal cells have reduced capability to decidualise in 
endometriosis (Klemmt et al., 2006). IL-11 enhances decidualisation of endometrial stromal 
cells normally (Dimitriadis et al., 2002) but its levels are reduced in endometriosis-associated 
infertility (Dimitriadis et al., 2006) which may interfere with implantation of embryo. 
Similarly, production of leukaemia inhibitory factor (LIF) - a marker of endometrial 
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receptivity produced by lymphocytes - is decreased in endometriosis-associated infertility 
(Achache and Revel, 2006, Dimitriadis et al., 2006).   
 
The results of this project suggest a generalised increase in the proportions of live 
lymphocytes in infertile women with endometriosis in the proliferative phase compared to 
fertile women with the disease. Since not all women with endometriosis are infertile, it 
appears that women with endometriosis, who have increased viability of immune cells in the 
proliferative phase, are more likely to be infertile.    
 
6.5.2 CD4+ CELLS 
A significant increase in endometrial CD4+ count was observed in the proliferative phase in 
infertile women with endometriosis compared to the secretory phase. These changes in CD4+ 
numbers were not observed in fertile women with endometriosis. Similar but less marked 
findings were observed in blood of infertile women with endometriosis. Although the 
numbers of CD4+ lymphocytes or their sub-populations in endometrium and blood have not 
been studied previously in infertility in endometriosis, it has been reported that Th-1 and Th-
2 blood cytokine profiles do not differ between women with endometriosis-associated 
infertility and controls (Podgaec et al., 2010). As the function of CD4+ cells is altered in 
endometriosis (Mettler et al., 1996) and infertility before implantation (Sykes et al., 2012), 
increased survival of live immune cells in infertile women with endometriosis before 
implantation may alter the favourable endometrial conditions, which may be due to increased 
resistance to apoptosis or secondary to reduced suppression by Tregs in the proliferative 
phase.  
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6.5.3 Tregs  
Treg density appeared to increase in infertile women with endometriosis in the proliferative 
phase compared to fertile controls with endometriosis. Although less marked, a similar trend 
was also observed in blood of infertile participants with endometriosis compared to fertile 
women with the disease. An increase in Treg density in fertile women with endometriosis in 
the proliferative phase may suppress other immune cells and increase chances of embryo 
implantation.  
 
The current findings build on previous indications of Foxp3 and Treg disturbances in 
endometriosis-associated infertility. André  et al (2011) have previously studied various 
endometrial Foxp3 genetic polymorphisms in infertile women with endometriosis compared 
to women with unexplained infertility and fertile controls. They demonstrated that the 
expression of certain Foxp3 polymorphisms is related to the presence of infertility in 
endometriosis. Endometrial Treg numbers and function in endometriosis and associated 
infertility may be determined by the presence or absence of certain Foxp3 polymorphisms 
which may relate to the fact that not all women with endometriosis are infertile and infertility 
in endometriosis is independent of the stage of the disease (Koch et al., 2012). 
 
6.6 LIMITATIONS OF THE STUDY 
The power calculation indicated that more samples would be ideal but analyses were 
restricted by small sample sizes, particularly in the menstrual phase. Unfortunately it was not 
feasible to increase numbers within the scope of this research degree candidature and it 
should be noted that the study participants represent a year of full-time recruitment and 
thorough review of tissue archives. Some other limitations of this study were:  
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 Immune cells show day-to-day variations in the menstrual cycle. Analysis in the early, 
mid and late parts of each phase was not able to be performed due to limited numbers 
of participants in each phase, which may have affected the results. 
 IHC was performed on a cohort of patients, which included participants for whom 
samples were not available for flow cytometry (although most participants in flow 
cytometry experiments were also included in IHC).   
 Treg sub-populations were not analysed separately. Individual Treg subpopulations, 
which may have different proportions in the total Treg pool, may play individual roles 
during the normal menstrual cycle and in endometriosis and infertility.  
 Functional analyses were not performed in our study. Function of Tregs is reported to 
be altered in endometriosis and infertility. Tregs may have disturbed function in these 
conditions despite normal numbers.  
 
6.7 CONCLUSIONS 
Overall, this project showed important differences in the numbers of blood and endometrial 
lymphocyte populations in women with endometriosis and between fertile and infertile 
women. The most interesting finding, which has not been reported before, was the increased 
survival of live lymphocytes in the endometrium and blood in patients with endometriosis, 
infertility and endometriosis-associated infertility. This finding was most evident in the 
proliferative phase of the menstrual cycle. Increased numbers of live immune cells in the 
proliferative phase may alter the endometrial environment before implantation of the embryo.   
 
This thesis also demonstrated decreased numbers of endometrial Tregs in infertile women in 
the proliferative phase compared to fertile women. It appears that increased survival of 
immune cells before implantation in infertile women may be directly related to decreased 
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suppression of immune response by Tregs. This study also indicates that in endometriosis, 
infertility and endometriosis-associated infertility, an unfavourable endometrial immune 
environment for implantation may be established much earlier (in the proliferative phase) in 
the menstrual cycle than was previously recognised. Altered immune responses in the 
endometrium during this period may contribute to the establishment of an endometrial 
environment unfavourable for implantation. 
The specific conclusions of this study with respect to the original aims and hypotheses are as 
follows: 
 Overall, the numbers of circulating and endometrial Tregs appear to vary throughout 
the menstrual cycle, with some subtle differences evident between fertile and infertile 
women and in participants with and without endometriosis.  
 No dramatic changes occur in circulation or the endometrium of women with 
endometriosis in the secretory phase compared to women without the disease. 
However, Treg numbers in circulation and blood appear to increase in the secretory 
phase in women with endometriosis compared to controls.  
 Endometrial numbers of Tregs appear to decrease in infertile women compared to 
fertile women in the menstrual cycle which is significant in the proliferative phase. 
No dramatic changes occur in Treg density in circulation of infertile women 
compared to fertile participants throughout the menstrual cycle. 
 The numbers of endometrial Tregs appear to decrease in infertile women with 
endometriosis compared to fertile women with the disease in the proliferative and 
secretory phases. Similarly, Treg numbers in blood do not vary markedly between 
fertile and infertile women with endometriosis. Treg analysis in blood in women 
without endometriosis was restricted by small number of participants.  
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6.8 FUTURE DIRECTIONS 
The results of this project indicate important alterations in Tregs and other lymphocyte 
populations in endometriosis and infertility, which has given rise to some interesting 
questions that need to be answered. Future studies could include the following: 
 Day-to-day analysis of immune cell populations in blood and the endometrium during 
the menstrual cycle in endometriosis, infertility and endometriosis-associated 
infertility.    
 Mechanisms governing apoptosis in immune cells in blood and the endometrium in 
endometriosis, infertility and endometriosis-associated infertility. 
 Assessment of viability of shed endometrial fragments and immune cell populations 
in endometriosis and infertility using cell culture techniques. 
 Identification of specific cell markers for Treg sub-group analysis in endometriosis 
and infertility. 
 Functional analyses of Tregs and sub-groups in endometriosis and infertility.  
 Investigation of whether specific Treg subsets are recruited into the endometrium at 
various phases of the menstrual cycle. 
 Analysis of migration of immune cell populations between blood, peritoneal cavity 
and the endometrium in the normal menstrual cycle, endometriosis and infertility in 
all phases.  
 Studies to determine Treg genetic polymorphisms in endometriosis, infertility and 
endometriosis-associated infertility. 
 
These studies are likely to improve our understanding of the immunological mechanisms that 
underlie endometriosis, infertility and endometriosis-associated infertility. Better 
understanding of the immunological alterations in these reproductive pathologies may help 
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develop new strategies to prevent them in high risk populations, improve implantation rates 
and reduce sub-clinical pregnancy loss.  
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APPENDICES 
 
APPENDIX A 
PREPARATION OF BUFFER 
Buffer solution was prepared by mixing 0.5 gram of bovine serum albumin and 1 tablet of 
phosphate buffered saline (Dulbecco ‘A’ Tablets, Oxoid limited, UK) per 100 mL of distilled 
water until they were completely dissolved.  
 
APPENDIX B 
PREPARATION OF PHOSPHATE BUFFERED SALINE  
Phosphate buffered saline (PBS) solution was prepared by adding one tablet of PBS 
(Dulbecco ‘A’ Tablets, Oxoid limited, UK) per 100 mL of distilled water.  
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